






- 1 **DELTA GRAND OKANAGAN**
1310 Water St • (250) 763-4500
- 2 **RESIDENT SOCIAL** WEDNESDAY 5:00–7:00pm
BNA BREWING COMPANY & EATERY
1250 Ellis St • (236) 420-0025
- 3 **WELCOME RECEPTION** THURSDAY 7:00–10:00pm
THE LAUREL PACKINGHOUSE
1304 Ellis St • (778) 478-0325
- 4 **CROF FUN RUN/WALK** FRIDAY 6:00 – 7:00pm
MEET ON THE BOARDWALK
AT THE BACK OF THE HOTEL AT 5:45pm
- 5 **DINNER & AWARDS CEREMONY** FRIDAY 7:00pm
MISSION HILL WINERY
1730 Mission Hill Road • (250) 768-7611
- 6 **NINE AND DINE**
THE HARVEST GOLF CLUB SATURDAY 2pm
2725 KLO Road • (250) 862-3103





CARO Board of Directors

Ross Halperin, *President*
Eric Vigneault, *President Elect*
Jacqueline Spayne, *Secretary-Treasurer*
Naseer Ahmed
Andrea Bezjak, *Past President*
Amanda Caissie
George Rodrigues
Isabelle Roy
Vikram Velker

Guest Faculty

Søren Bentzen, *CARO Lecturer*
Michael Milosevic, *Gordon Richards Lecturer*
Mira Keyes, *Jean-Roy Lecturer*
Robert Bristow, Kim Chi, Bradly Wouters
Theme Symposium Speakers

CARO Scientific Meeting Committee

Chandra Martens, *ASM Chair*
Amanda Caissie
Marc Gaudet
Meredith Giuliani
Marie-Pierre Milette
Gunita Mitera
Angela Turner
Derek Wilke
Mary Hooey, *ASM Coordinator*
Kim O'Hearn, *ASM Recorder*
Jenny Gleanz, *Association Coordinator*
Narma Yogan, *Senior Association Coordinator*

Learning Objectives

The theme of the meeting is Brachytherapy and Biology.

By the end of the conference, the participants will be able to:

- describe how the biology of our cells and the intricacies of the reactions taking place are impacted by radiation;
- identify how we can use this information to improve patient treatments, and ultimately cancer control and cure with Radiation Medicine.

Don't miss this opportunity to connect with colleagues in radiation medicine across Canada.

Accreditation

This event is an accredited group learning activity under Section 1, as defined by the Royal College of Physicians and Surgeons of Canada for the *Maintenance of Certification* Program.

Accreditation has been approved for:

- Canadian Association of Medical Radiation Technologists (CAMRT) – 17 Category A Credits.
- Medical Dosimetrist Certification Board (MDCB) 6 CE Credits.
- University of British Columbia 22.5 CFredits (Section 1 MOC).

Presentations

All oral presentations in this program contain 25% for interactivity.

- 90-minute presentations include 60-minute talk, 30-minute question and answer period.
- 60-minute presentations include 45-minute talk, 15-minute question and answer period.
- 10-minute presentations include 7-minute talk, 3-minute question and answer period.



TABLE OF CONTENTS

LETTER FROM THE PRESIDENT	ii
LETTER FROM THE ASM CHAIR	iv
Wednesday, September 9 Preconference	1
CARO RESIDENT REFRESHER COURSE	1
CANADIAN BRACHYTHERAPY ORAL SESSION	1
THURSDAY, September 10	2
THEME SYMPOSIUM - BIOLOGY AND RADIATION	2
CARO LECTURE	2
POSTER DISCUSSION SESSION 1	3
POSTER DISCUSSION SESSION 2	4
ORAL SESSION 1 – BRACHYTHERAPY	5
ORAL SESSION 2 – HEAD AND NECK	6
ORAL SESSION 3 – POPULATION SCIENCE AND HEALTH SCIENCES	7
FRIDAY, SEPTEMBER 11	8
GORDON RICHARDS LECTURE	8
RESIDENT COMPETITION	8
FELLOW COMPETITION	9
ORAL SESSION 4 – APPLIED PHYSICS AND TECHNOLOGY	9
ORAL SESSION 5 – LUNG	10
ORAL SESSION 6 – CNS AND RADIOSURGERY	11
JEAN ROY LECTURE	11
SATURDAY, SEPTEMBER 12	12
ORAL SESSION 7 – GU CANCER	12
ORAL SESSION 8 – BREAST AND EDUCATION	13
ORAL SESSION 9 – VARIETY PACK	14
CONCURRENT WORKSHOPS	15
REVIEWER'S CHOICE	16
Poster Abstracts	17



ROSS HALPERIN
CARO PRESIDENT

Dear Colleagues,

Welcome to the 29th CARO Annual Scientific Meeting. Dr. Chandra Martens, Mary Hooey and the ASM committee have organized another great slate for the 2015 CARO ASM. In Kelowna our CARO members will congregate and continue their tradition of engagement in scholarly activity. This year 229 abstracts were accepted and these projects and presentations will stimulate us, improve our knowledge and inspire tomorrow's hypotheses.

CARO's ASM is more than a scientific meeting, it's also a joyous get together and an unparalleled networking opportunity. Our warm experience in St John's was in keeping with that sentiment. We renewed friendships whilst pushing excellence. It's my privilege to welcome CARO to my home, Kelowna BC. Kelowna's backdrop will make this a memorable CARO ASM: Located in the heart of wine country and affectionately known as "Napa of the North", Kelowna and the Okanagan's Vineyard strength is built upon its warm dry climate and history of orchard agriculture. Today, Vineyard tourism is amongst the many reasons tourists come to the Okanagan.

This year's theme *Brachytherapy and Biology* speaks to the origins and foundation of modern Radiation Oncology. Early reports of clinical efficacy of radiation therapy for cancer was initially demonstrated with radium placed in proximity to tumours—the original brachytherapy. In our practices we seek to optimize the therapeutic ratio and our quest to do so drives our interest in tumour biology and genetics. Likewise we strive to optimize the delivery in time and space of maximal radiation to the tumour target whilst minimizing the dose to surrounding normal tissues. At the CARO ASM will hear of SBRT, 4DCRT, IMRT, IGRT and yet our theme reminds us that brachytherapy remains for some deep seated tumours the optimal way to treat the tumour and minimize dose to normal tissues and thereby maximize tumour control and minimize morbidity. Hence we embrace modern effective brachytherapy whilst we move forward towards a better future for the patients we serve, enabled by modern biological understanding.

This year's Gordon Richards Lecturer is Dr. Michael Milosevic; *Targeting Cancer at the Biology - Technology Interface*. The CARO lecture will be given by Dr. Søren Bentzen who will speak on; *Reintegrating Biology into the Scientific Basis of Radiation Oncology*. There will be two theme symposia; Dr. Robert Bristow. Dr. Brad Wouters and Dr. Kim Chi will lead us through a symposium on current issues in biology covering hypoxia, the tumour microenvironment, genomics, profiling and phenotypic diversity. The Canadian Brachytherapy Group has invited Dr. Mira Keyes to give the brachytherapy focused Jean Roy Lecture.

This year we will run the Pamela Catton Memorial Run/Walk in support of CROF on Thursday, September 10th at 6:00pm. Come run, walk or cheer with us as the sun fades behind the mountains; as we honour the terrific commitment and contributions of x Catton. I hope you've all been training to beat the CARO president. I've kept up my preparation, running monthly or more whether I need to or not! For everyone who crosses the finish line before me I will donate \$10 to CROF. For those very few who don't run faster than I do, do not despair: For every walk or run participant I will contribute \$5! Come and join us and bring your friends and colleagues along.

Of course, don't forget the social activities. We start with the Welcome Reception at the Laurel Packinghouse located down the street from the hotel. Our Awards and Dinner Ceremony will be at Mission Hill Winery. I hope you purchased your ticket! If you did not purchase a ticket and want would like to attend, check at the registration desk.

Welcome to my home town and I anticipate you will enjoy a fun, stimulating CARO ASM.

Ross Halperin MD FRCPC
President, CARO



ROSS HALPERIN
ACRO PRÉSIDENT

Chers collègues,

Bienvenue à la 29^e réunion scientifique annuelle (RSA) de l'Association canadienne de radio-oncologie (ACRO). La Dre Chandra Martens, Mary Hooey et le comité de la RSA nous ont concocté un autre formidable programme pour la RSA 2015 de l'ACRO. Les membres de l'ACRO se réuniront à Kelowna et, comme le veut la tradition, ils prendront part à des activités érudites. Cette année, 229 résumés ont été acceptés. Ces projets et présentations contribueront à stimuler notre réflexion et à accroître nos connaissances, et nous aideront à formuler les hypothèses de demain.

La RSA de l'ACRO est plus qu'une réunion scientifique, c'est aussi l'occasion d'un joyeux rassemblement qui offre des perspectives de réseautage sans pareilles. Nos chaleureuses retrouvailles à St. John's s'inscrivaient dans cette ligne. Nous avons renoué des amitiés, tout en poursuivant notre quête d'excellence. C'est pour moi un privilège d'accueillir l'ACRO chez moi, à Kelowna, en Colombie Britannique. Nul doute que le panorama spectaculaire de Kelowna sera de nature à faire de cette RSA de l'ACRO un événement des plus mémorables : les exploitations vinicoles de Kelowna et de l'Okanagan, situées au cœur du pays du vin qu'on surnomme affectueusement « Napa du Nord », sont reconnues pour leur dynamisme qui repose sur un climat chaud et sec et une tradition de culture de vergers. Aujourd'hui, le tourisme vinicole est l'un des segments en plein essor de l'industrie touristique de la région de l'Okanagan.

Le thème de cette année « Curiethérapie et biologie » porte sur les origines et le fondement de la radio-oncologie moderne. Les premières démonstrations de l'efficacité clinique de la radiothérapie dans le traitement du cancer ont d'abord été faites avec du radium placé à proximité de la tumeur – curiethérapie classique. Dans nos pratiques, nous cherchons à optimiser l'index thérapeutique, et cette aspiration motive notre intérêt pour la biologie et la génétique des tumeurs. De même, nous tâchons d'optimiser dans l'espace et le temps l'administration d'une dose maximale de radiation à la tumeur cible, tout en réduisant au minimum l'irradiation des tissus sains environnants. À la RSA de l'ACRO, nous entendrons parler de la radiothérapie corporelle stéréotaxique, de la radiothérapie conformationnelle 4D, de la radiothérapie conformationnelle avec modulation d'intensité et de la radiothérapie guidée par l'image; cependant, notre thème nous rappelle que la curiethérapie demeure une façon optimale de traiter certaines tumeurs profondes et de réduire au minimum la dose reçue par les tissus sains, permettant ainsi de maximiser le contrôle de la tumeur et de diminuer la morbidité. C'est pourquoi nous prônons une curiethérapie

efficace et moderne, tandis que nous progressons, grâce à nos acquis récents en biologie, vers un avenir meilleur pour les patients que nous servons.

Cette année, la conférence Gordon Richards sera donnée par le Dr Michael Milosevic et s'intitulera : Cibler le cancer avec des outils à la frontière entre la biologie et la technologie. La conférence de l'ACRO sera prononcée par le Dr Søren Bentzen et aura pour sujet : Réintégrer la biologie dans les fondements scientifiques de la radio-oncologie. Il y aura deux symposiums thématiques. Le Dr Robert Bristow, le Dr Brad Wouters et le Dr Kim Chi animeront un symposium sur des questions actuelles de biologie, dont l'hypoxie, le microenvironnement tumoral, la génomique, le profilage et la diversité phénotypique. Le Groupe canadien de curiethérapie a invité le Dr Mira Keyes à donner la conférence Jean Roy axée sur la curiethérapie.

Cette année, la course/marche commémorative Pamela Catton pour la Fondation canadienne de radio-oncologie (FCRO), se tiendra le jeudi 10 septembre, à 18 h. À l'heure où le soleil disparaît derrière les montagnes, venez courir, marcher ou encourager les participants avec nous pour rendre hommage à l'engagement et aux contributions remarquables de la Dre Pamela Catton. J'espère que vous vous êtes tous entraînés pour battre le président de l'ACRO. En ce qui me concerne, je me suis bien préparé en courant une fois par mois ou plus, que j'en aie besoin ou pas! Pour toute personne qui franchira la ligne d'arrivée avant moi, je ferai un don de 10 \$ à la FCRO! Quant aux quelques rares coureurs plus lents que moi, ne désespérez pas : pour chaque participant à la marche ou à la course, je verserai 5 \$! Venez vous joindre à nous et amenez vos amis et vos collègues.

Bien sûr, n'oubliez pas les activités sociales. Nous donnerons le coup d'envoi avec la réception d'accueil au Laurel Packinghouse situé dans la même rue que l'hôtel. Le souper et la cérémonie de remise de prix se dérouleront au Mission Hill Winery. J'espère que vous avez acheté vos billets! Si vous n'avez pas de billet et que vous souhaitez participer à l'événement, adressez-vous au bureau d'inscription.

Je vous souhaite la bienvenue dans ma ville et je suis certain que vous apprécierez cette RSA de l'ACRO qui promet d'être plaisante et stimulante.

Ross Halperin, MD, FRCPC
Président de l'ACRO



CHANDRA MARTENS
THE ASM CHAIR

Dear CARO Attendees,

The ASM Committee and I are excited to bring you the *2015 CARO Annual Scientific Meeting* from Kelowna, in beautiful British Columbia!

Thank you for joining us for *Brachytherapy and Biology* — and the many wonderful activities in the beautiful interior of British Columbia.

This meeting has a schedule full of interesting and varied speakers, a theme symposium, poster presentations, workshops, and, as always, at the CARO ASM, many cool, fun and lively social events! — all taking place in venues capturing all that the beautiful Kelowna has to offer.

The pre-conference activities start Wednesday with the Resident Refresher Course and Canadian Brachytherapy Group. The rest of the week includes interesting oral presentations from our colleagues across Canada, several keynotes, a poster viewing session and discussion sessions, theme symposium, resident competition, fellow competition, reviewer's choice, and this year, the return of the popular Workshop sessions!

The CROF Fun Run/Walk, has been renamed in honor of our beautiful colleague, Dr. Pamela

Catton, who left us all far too early, and with a great void this year, and in her honor this event will now be called The Pamela Catton Memorial Run/Walk for CROF. It will take place along the beautiful lakeside boardwalk. We invite you all to join us for this very special inaugural event.

Other meeting highlights include:

- The brand new Contouring Workshop
- The Resident Social
- CARO, Gordon Richards, Jean Roy Memorial Lectures
- Theme Symposium
- Workshops
- Winery Tours
- Golf

This promises to be another great meeting with something for absolutely everyone, in one of Canada's most beautiful locations, interior British Columbia!

Welcome to Kelowna, for a few days of relaxation, education, life-long learning, networking and socializing with your friends and colleagues.

Thanks for being here!

Chandra Martens MD FRCPC
Chair, ASM Committee



CHANDRA MARTENS

PRÉSIDENTE, COMITÉ DE PLANIFICATION DU CSA

Chers participants de l'Association canadienne de radio-oncologie (ACRO),

Le comité de la Réunion scientifique annuelle (RSA) et moi-même avons le plaisir de vous présenter la RSA 2015 de l'ACRO depuis Kelowna, dans la magnifique province de la Colombie-Britannique! Ne manquez rien de cet événement qui se déroule du 9 au 12 septembre!

Merci de vous joindre à nous pour la RSA qui porte sur la curiethérapie et la biologie – et de participer aux nombreuses belles activités dans le splendide décor de l'intérieur de la Colombie-Britannique.

Le programme ambitieux de la réunion vous proposera une foule de conférenciers captivants et variés, un symposium thématique, des présentations par affiches, des ateliers et, comme toujours à la RSA de l'ACRO, beaucoup d'activités sociales sympathiques, amusantes et animées – le tout dans un cadre enchanteur qui vous permettra de découvrir toutes les splendeurs de Kelowna.

Les activités préalables à la conférence commenceront mercredi avec le cours de recyclage des résidents et le Groupe canadien de curiethérapie. Le reste de la semaine sera consacré à différentes activités, dont des présentations orales intéressantes de nos collègues de partout au Canada, plusieurs discours-programmes, une séance de présentation par affiches et des séances de discussion, un symposium thématique, un concours des résidents, un concours des boursiers, une activité au choix de l'examineur, et cette année, le retour des très populaires séances d'ateliers!

La course/marche pour la Fondation canadienne de radio-oncologie (FCRO) a été renommée en hommage à notre remarquable collègue, la Dre Pamela Catton, qui nous a quittés beaucoup trop tôt, laissant un très grand vide cette année, et en son honneur cet événement s'appellera désormais la course/marche commémorative Pamela Catton pour la FCRO. Le parcours empruntera la superbe promenade en bordure du lac, et nous vous invitons tous à vous joindre à nous pour cet événement inaugural très spécial.

D'autres activités importantes de la réunion comprendront :

- le tout nouvel atelier sur le contournage;
- l'activité sociale pour les résidents;
- la conférence de l'ACRO, la conférence de Gordon Richards et la conférence commémorative Jean Roy;
- le symposium thématique;
- les ateliers;
- les visites d'établissements vinicoles;
- le golf.

Voilà une autre réunion qui promet d'être mémorable avec des activités pour tous les goûts, dans l'une des plus belles régions du Canada, l'intérieur de la Colombie-Britannique!

Bienvenue à Kelowna pour quelques jours de relaxation, de formation, d'apprentissage continu, de réseautage et de socialisation avec vos amis et collègues.

Merci d'être venus!

Chandra Martens MD FRCPC
Chair, ASM Committee

Canadian Radiation Oncology Foundation • Fondation canadienne de radio-oncologie



THE PAMELA CATTON MEMORIAL RUN/WALK FOR CROF

CROF  FCRO

Thursday, September 10, 6pm

Meet on the boardwalk at the back of the hotel at 5:45pm

WEDNESDAY, SEPTEMBER 9, 2015

PRECONFERENCE

6:45-1:30 CARO RESIDENT REFRESHER COURSE *Vaseaux/Kootenay*

Facilitators: Meredith Giuliani, Vikram Velker

OBJECTIVES: Upon completion of this refresher course, the attendees should be able to:

- review the principles of management of common cancers;
- understand the technology that underpins cone-beam CT and common misconceptions about CBCT;
- review and practice volume generation in compliance with the GEC-ESTRO guidelines.

6:45-7:30 REGISTRATION AND BREAKFAST

7:45-8:00 WELCOME AND INTRODUCTIONS

7:45-8:30 OROPHARYNX John Waldron

8:30-9:15 NASOPHARYNX George Shenouda

9:15-10:00 IGRT PRIMER James Loudon, Andrew Hope

10:00 -10:15 Break

10:15 -11:00 LYMPHOMA Richard Tsang

11:00 -11:45 PROSTATE AND PENILE BRACHYTHERAPY Juanita Crook

11:45 -12:45 Lunch

12:45 -1:30 THYROID WITH RAI John Hay

1:30-2:30 CANADIAN BRACHYTHERAPY ORAL SESSION

Moderators: Marc Gaudet, Eric Vigneault

OBJECTIVES: Participants will learn about updated brachytherapy topics including; treatment and GI toxicity in cervical cancer patients, high dose brachytherapy and lower GI tumours, HDR and bulky endometrial cancer treatment, brachytherapy used for endobronchial treatments, plesio-brachytherapy in penile cancer, and MRI based cervical tumour CTV coverage.

- 1 RADIATION TREATMENT PARAMETERS AND LATE GASTROINTESTINAL TOXICITY IN CERVICAL CANCER PATIENTS TREATED WITH IMAGE-GUIDED HIGH DOSE RATE BRACHYTHERAPY** Sarah Hamilton¹, Marc Gaudet², Peter Lim¹, Christina Parsons¹ ¹British Columbia Cancer Agency, Vancouver, BC; ²CCSS de Gatineau, Hôpital Gatineau, Gatineau, QC

- 2 HIGH-DOSE RATE BRACHYTHERAPY: AN EFFECTIVE TREATMENT FOR LOWER GASTROINTESTINAL MALIGNANCIES** Nhu-Tram A. Nguyen, Emilia Timotin, Robert Hunter, Ranjan K Sur Juravinski Cancer Centre, McMaster University, Hamilton, ON

- 3 HIGH-DOSE RATE (HDR) INTERSTITIAL BRACHYTHERAPY FOR THE TREATMENT OF BULKY LOCALLY RECURRENT ENDOMETRIAL CARCINOMA: A SINGLE-INSTITUTION EXPERIENCE** Kitty Huang¹, David D'Souza¹, Nikhilesh Patil², Eric Leung³, Tammie Murray⁴, Leanne Derrah⁴, Elizabeth Jewlal⁴, Larry Stitt¹, Akira Sugimoto⁴, Jacob McGee⁴, Michel Prefontaine⁴; ¹London Regional Cancer Program, London,

ON; ²Nova Scotia Cancer Centre, Halifax, NS; ³Odette Cancer Centre, Toronto, ON; ⁴London Health Sciences Center, London, ON

- 4 BRACHYTHERAPY AS A TREATMENT OPTION OF ENDOBRONCHIAL TUMOURS** Andrew McPartlin, Ali Hosni, Saibishkumar Elantholi Parameswaran, Alexandra Rink, Kasia Czarnecka, Susan Paterson, Andrea Bezjak University of Toronto, Toronto, ON

- 5 CUSTOMIZED PENILE PLESIORACHYTHERAPY USING LATEST STEREOLITHOGRAPHY TECHNIQUES** Joelle Helou¹, Gerard Morton², Easton Harry², Linda Jurincic², Laura D'Alimonte², Ananth Ravi²; ¹University of Toronto, Toronto, ON; ²Sunnybrook Odette Cancer Centre, Toronto, ON

- 6 3D MRI BASED BRACHYTHERAPY FOR CERVICAL CANCER IMPROVED HIGH-RISK CTV COVERAGE** Theodora Koulis¹, Corinne Doll¹, Laurel Traptow², Tien Phan¹; ¹University of Calgary, Calgary, AB; ²Tom Baker Cancer Centre, Calgary, AB

2:30-4:00 GYNE CONTOURING WORKSHOP David D'Souza

4:15-6:15 RESIDENT SOCIAL *BNA Brewing Company & Eatery, 1250 Ellis Street, (236) 420-0025* (CARO Board members invited for the first 30 minutes)

5:00-8:00 CARO BOARD MEETING *Cascade/Cassiar*

THURSDAY, SEPTEMBER 10, 2015

7:15-8:15	MEET AND GREET (by invitation) <i>Upper Terrace</i>
7:30-8:20	REGISTRATION AND BREAKFAST
8:20-8:45	WELCOME AND INTRODUCTIONS <i>Okanagan</i> Ross Halperin TRIBUTE TO PAMELA CATTON Chandra Martens, Nicole Harnett
8:45-10:15	Theme Symposium – Biology and Radiation Moderators: Robert Bristow, Bradly Wouters, Kim Chi
	GENETIC INSTABILITY AND HYPOXIA DRIVE PROGNOSIS IN PROSTATE CANCER: IMPLICATIONS FOR CHANGING TREATMENT Robert Bristow
	OBJECTIVES: At the end of this session, the participants will be able to: - understand the importance of hypoxia in tumour progression and aggression; - appreciate the importance of genomic medicine in individualizing prognosis in prostate cancer; - develop an understanding of how the tumour microenvironment may interact with genomics and give the clinician more information on how to individualize treatment that either aspect alone.
	THERAPEUTIC CHALLENGES AND OPPORTUNITIES RESULTING FROM PHENOTYPIC DIVERSITY IN TUMOURS Bradly Wouters
	OBJECTIVES: At the end of this session, the participants will be able to: - describe different types of phenotypic diversity in tumours; - describe how phenotypic diversity arises due to hypoxia; - describe opportunities for treatments based on targeting diversity.
	PRECISION MEDICINE FOR CASTRATION RESISTANT PROSTATE CANCER Kim Chi
	OBJECTIVES: At the end of this session, the participants will be able to: - understand the limitations of the current treatments for CRPC; - review recent advances in the bioprofiling of patients with CRPC; - describe ongoing and planned clinical trials of CRPC with integrated biomarkers.
10:15-11:00	POSTER VIEWING/BREAK <i>Grand Foyer/Shuswap/Pennask/Skeena</i>
11:00-12:00	CARO Lecture Introduction: Ross Halperin REINTEGRATING BIOLOGY INTO THE SCIENTIFIC BASIS OF RADIATION ONCOLOGY Søren Bentzen
	OBJECTIVES: At the end of this session, the participants will be able to: - describe the synergy between advances in radiation therapy planning and delivery on one hand and advances in molecular and cancer biology on the other; - to recognize the difference between statistical significance and clinical utility.
12:00-2:00	<i>Lunch Break</i>
12:00-1:00	<i>COMMITTEE MEMBER LUNCH</i>
1:00-1:45	COMMITTEE MEETINGS

2:30-3:30 **POSTER DISCUSSION SESSION 1** *Okanagan*

Moderators: Gerard Morton, Alan Nicol

OBJECTIVES: At the end of this session, the participants will be able to:

■ understand Metformin and mortality from lower cervical cancer, normal tissue toxicity with breast boost, planning CT scans/HDR vaginal brachytherapy and dose to OAR, the metrics for measuring skin dose in breast brachytherapy, 18-FCH and PET/MRI hybrid scans in men with suspected prostate cancer recurrence, prostate apex contouring, applying trial data to real life prostate cancer patients, locally advanced head and neck cancer patients and the impact of RT technique, cisplatin dose, and HPV status, RT and T1 and T2 glottic cancer outcomes from an institutional study, natural course of HPV + and HPV - oropharyngeal cancers following chemoradiation therapy, and EGFR status and metastatic behavior of tumours in small cell lung cancer.

-
- 150 METFORMIN USE IS ASSOCIATED WITH LOWER CERVICAL CANCER-SPECIFIC MORTALITY** Kathy Han¹, Melania Pintilie¹, Lorraine L Lipscombe², Iliana Lega², Michael Milosevic¹, Anthony Fyles¹; ¹Princess Margaret Cancer Centre, Toronto, ON; ²Women's College Hospital, Toronto, ON
-
- 115 PROSPECTIVE EVALUATION OF NORMAL TISSUE TOXICITY ASSOCIATED WITH BREAST BOOST IN EARLY-STAGE BREAST CANCER RADIOTHERAPY** Grace Lee, Nafisha Lalani, Nora Emad, Bethany Gill, Tony Panzarella, Anne Koch; Princess Margaret Cancer Centre, Toronto, ON
-
- 98 PLANNING CT SCANS FOR THE TREATMENT OF HDR VAGINAL VAULT BRACHYTHERAPY: AN EVALUATION OF ITS ROLE TO DETERMINE THE DOSE TO THE ORGANS AT RISK** Tracey Rose, Deidre Batchelar, Bart Robertson, Juanita Crook, David Petrik, Francois Bachand; University of British Columbia, Kelowna, BC
-
- 97 MEASURING SKIN DOSE IN BREAST BRACHYTHERAPY: DOES IT MATTER WHAT METRIC WE USE?** Michelle Hilts¹, Heather Halperin¹, Daniel Morton², Deidre Batchelar¹, Francois Bachand¹, Rezwan Chowdhury¹, Juanita Crook¹; ¹British Columbia Cancer Agency, Southern Interior, Kelowna, BC; ²University of Victoria, Victoria, BC
-
- 134 18F-FLUOROCHOLINE (18F-FCH) HYBRID PET/MRI IN THE EVALUATION OF MEN WITH SUSPECTED PROSTATE CANCER RECURRENCE FOLLOWING DEFINITIVE LOCAL THERAPY: A PROSPECTIVE STUDY** Tina W. Zhang¹, Zahra Kassam², Irina Rachinsky¹, Cesare Romagnoli¹, David D'Souza¹, Varagur Venkatesan¹, Belal Ahmad¹, Joseph Chin¹, Stephen Pautler¹, John Butler¹, Jonathan Thiessen¹, Ashley Lozanski¹, Peter Chung², Cynthia Menard², Ty Lee¹, Glenn Bauman¹; ¹Western University, London, ON; ²University of Toronto, Toronto, ON
-
- 135 ARE RESULTS FROM INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED WITHIN CLINICAL TRIALS APPLICABLE TO REAL LIFE PATIENTS?** Xavier Liem, Jean-Paul Bahary, Guila Delouya, Marie-Claude Beauchemin, Carole Lambert, Maroie Barkati, Daniel Taussky Université de Montréal, Montréal, QC
-
- 136 PROSTATE APEX CONTOURING** Eduardo Gaviolli, Ian Dayes, Angela Lin, Gregory Pond, Thomas Chow; McMaster University, Hamilton, ON
-
- 153 CONCURRENT CHEMORADIOOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER: IMPACT OF RADIATION TECHNIQUE, CISPLATIN DOSE, AND TUMOUR HPV STATUS** Shao Hui Huang, Srefico Anne, Wei Xu, Chen Liu, John Waldron, Eric Chen, Jolie Ringash, Andrew Bayley, Kelvin Chan, Andrew Hope, Albiruni Razak, Bayardo Perez-Ordóñez, Ilan Weinreb, John Cho, Raymond Jang, Aaron Hansen, Yuyao Song, Brian O'Sullivan, Lillian Siu, John Kim; University of Toronto, Toronto, ON
-
- 152 OUTCOMES IN T1 GLOTTIC CANCER TREATED WITH RADIOTHERAPY: A SINGLE INSTITUTION EXPERIENCE** Tina W. Zhang¹, Tsu-Hui (Hubert) Low¹, David Yeh¹, Rakhna Araslanova¹, J. Alex Hammond¹, David A. Palma¹, Nancy Read¹, Kevin Fung¹, Danielle MacNeil¹, Anthony C. Nichols¹, John Yoo², Varagur Venkatesan¹; ¹Western University, London, ON; ²London Health Sciences Centre, London, ON
-
- 154 OUTCOMES OF STAGE II GLOTTIC CANCER IN A SINGLE INSTITUTION: CONVENTIONAL VERSUS INTENSITY MODULATED RADIOTHERAPY** Tina W. Zhang¹, Tsu-Hui (Hubert) Low¹, David Yeh¹, Rakhna Araslanova¹, J. Alex Hammond¹, David A. Palma¹, Nancy Read¹, Kevin Fung¹, Danielle MacNeil¹, Anthony C. Nichols¹, John Yoo², Varagur Venkatesan¹; ¹Western University, London, ON; ²London Health Sciences Centre, London, ON
-
- 155 NATURAL COURSE FOLLOWING FAILURE AFTER DEFINITIVE (CHEMO-) RADIOTHERAPY IN HPV-RELATED AND HPV-UNRELATED OROPHARYNGEAL CANCER** Shrinivas Rathod, Shao Hui Huang, John Kim, Susie Su, Wei Wu, John Waldron, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, Jolie Ringash, Aaron Hansen, David Goldstein, Li Tong, Bayardo Perez-Ordóñez, Ilan Weinreb, Brian O'Sullivan; Princess Margaret Cancer Centre, Toronto, ON
-
- 167 EGFR MUTATION STATUS ON THE METASTATIC BEHAVIOR OF NON-SMALL CELL LUNG CANCER** David Anderson¹, Alex De Caluwe¹, Ted Toriumi¹, Cheryl Ho², Fred Hsu¹; ¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Vancouver, BC
-

2:30-3:30 **POSTER DISCUSSION SESSION 2** *Columbia*

Moderators : Amanda Caissie, Melanie Reed

OBJECTIVES: At the end of this session, the participants will be able to:

■ understand the impact of prostate cancer on sex lives of men, treatment induced hearing loss and cochlear doses, hypofractionated palliative RT for advanced squamous cell carcinomas in head and neck, using a 0-7-21 course, using a video decision support aid for advanced cancer patients, radiosurgery, telemedicine and the clinical specialist radiation therapist role in patient access to care, outreach activities by cancer centres in Ontario, RT and Heterotopic ossification prevention —a look at the trials, locally advanced cervix cancer in young women despite screening programs, a look at the impact of the difficult Canadian job market on residents and program directors in radiation oncology, inhibiting myeloid cell recruitment and cervical cancer curability, quantitative digital pathology tool and predicting recurrent prostate cancer, familial prostate cancer clinic and male oncology research program at Sunnybrook.

227 THE IMPACT OF PROSTATE CANCER ON THE SEX LIVES OF MEN-WHO-HAVE-SEX-WITH-MEN (MSM): A QUALITATIVE STUDY Tsz Kin Lee¹, Ariel Handy², Richard Wassersug², Lori Brotto², Winkle Kwan³, John Oliffe², Gary Dowsett⁴; ¹British Columbia Cancer Agency, Kelowna, BC; ²University of British Columbia, Vancouver, BC; ³British Columbia Cancer Agency, Surrey, BC; ⁴La Trobe University, Melbourne, BC

226 TREATMENT-INDUCED HEARING LOSS AND COCHLEAR DOSES: DOES RADIATION STILL PLAY A ROLE IN THE IMRT ERA? Jelena Lukovic¹, Wendy Teft², Linda Lee², Anthony Nichols¹, Christina Parker², Maureen Trinear¹, Eric Winquist¹, John Yoo³, David Palma¹, Richard Kim²; ¹London Regional Cancer Program, London, ON; ²Western University, London, ON; ³London Health Sciences Centre, London, ON

190 PHASE II STUDY: 0-7-21 HYPOFRACTIONATED PALLIATIVE RADIOTHERAPY FOR ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS Nhu-Tram A Nguyen, Lilian Doerwald-Munoz, Jim Wright, Do-Hoon Kim, Stephen Sagar, David Ian; Hodson; McMaster University, Hamilton, ON

203 ADVANCED CANCER PATIENTS' PERSPECTIVES ON A VIDEO DECISION SUPPORT AID USED TO ENHANCE GOALS OF CARE DISCUSSIONS Petra Grendarova¹, Marilynne Hebert University of Calgary, Calgary, AB

205 RADIOSURGERY, TELEMEDICINE AND THE CLINICAL SPECIALIST RADIATION THERAPIST: ENHANCING ACCESS TO CARE Julie Blain¹, Jeffrey Greenspoon², William McMillan², Carol Potvin², Laura Walsh³, Michelle Aspden³, Anand Swaminath²; ¹Juravinski Cancer Centre, Hamilton, ON; ²McMaster University, Hamilton, ON; ³Ontario Telemedicine Network, Hamilton, ON

202 OUTREACH ACTIVITIES BY RADIOTHERAPY CENTRES IN ONTARIO Pierre-Yves McLaughlin¹, Michael Brundage¹, Pdraig Warde², Eric Guttierrez³, William J Mackillop¹; ¹Queen's University, Kingston, ON; ²University of Toronto, Toronto, ON; ³Cancer Care Ontario, Toronto, ON

204 RADIOTHERAPY FOR THE PROPHYLAXIS OF HETEROTOPIC OSSIFICATION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Srinivas Raman¹, Milica Milakovic², Marko Popovic², May Tsao¹, Edward Chow¹; ¹University of Toronto, ON; ²McMaster University, Hamilton, ON

124 WHY ARE YOUNG WOMEN GETTING LOCALLY ADVANCED CERVIX CANCER DESPITE SCREENING? David D'Souza¹, Nikhilesh Patil², Eric Leung³, Elizabeth Jewlal¹, Heather Shaddick¹, Akira Sugimoto¹, Jacob McGee¹, Michel Prefontaine¹; ¹Western University, London, ON; ²Dalhousie University, Halifax, NS; ³University of Toronto, Toronto, ON

123 A MIXED METHODS SURVEY ON THE IMPACT OF A DIFFICULT CANADIAN JOB MARKET ON RADIATION ONCOLOGY RESIDENTS AND PROGRAM DIRECTORS Joshua Giambattista¹, Shilo Lefresne¹, Rob Olson², Hannah Carolan¹, Shaun Loewen³; ¹University of British Columbia, Vancouver, BC; ²University of British Columbia, Prince George, BC; ³University of Manitoba, Winnipeg, MB

132 PLERIXAFOR INHIBITS MYELOID CEL RECRUITMENT AND IMPROVES THE RADIOCURABILITY OF CERVICAL CANCER Naz Chaudary, Melania Pintilie, Richard P. Hill, Michael Milosevic; University of Toronto, Toronto, ON

183 EVALUATION OF A NOVEL QUANTITATIVE DIGITAL PATHOLOGY (QDP) TECHNIQUE AS A TOOL FOR PREDICTING PROSTATE CANCER RECURRENCE Andrea Lo¹, Calum MacAulay¹, Mira Keyes¹, Robert Bristow², Colin Collins¹, Ladan Fazli¹, Martin Gleave¹, Martial Guillaud¹, Jagoda Korbelik¹, Malcolm Hayes¹, Branko Palcic¹; ¹University of British Columbia, Vancouver, BC; ²University of Toronto, Toronto, ON

147 SUNNYBROOK FAMILIAL PROSTATE CANCER CLINIC (FPCC) AND MALE ONCOLOGY AND RESEARCH (MORE) PROGRAM Justin Lorentz, Gabriella Ghanem, Danny Vesprini; Odette Cancer Centre, Toronto, ON

3:30-3:50 **BREAK**

3:50-5:20 **ORAL SESSION 1 - BRACHYTHERAPY** *Skaha*

Moderators: Juanita Crook, Fabio Cury

OBJECTIVES: At the end of this session, the participants will be able to:

- || understand important concepts that affect brachytherapy treatments, such as dose delivery side effect profiles, toxicity, post implant dosimetry, cost of convenience, sexual recovery, hormonal recovery following treatments, and hear an update on neoadjuvant rectal brachytherapy.

- | | |
|---|---|
| <p>12 HIGH DOSE RATE ENDORECTAL BRACHYTHERAPY (HDREBT) A FIFTEEN-YEAR EXPERIENCE: CHALLENGES AND OPPORTUNITIES FROM NEOADJUVANT TO CURATIVE MODALITY FOR PATIENTS WITH RECTAL CANCER Té Vuong, Tamin Niazi, Gabriela Stroian, Jonathan Thebault, Alastair Sym, Slobodan Devic; Jewish General Hospital, Montréal, QC</p> | <p>11 TESTOSTERONE AND SEXUAL RECOVERY ANALYSIS AFTER CYTOREDUCTIVE RANDOMIZED THERAPY (DUTASTERIDE + BICALUTAMIDE VERSUS LHRH AGONISTS) PRIOR TO I-125 PERMANENT IMPLANT BRACHYTHERAPY FOR PROSTATE CANCER André-Guy Martin¹, Eric Vigneault¹, William Foster¹, François Meyer¹, Marc Gaudet²; ¹Université Laval, Québec, QC; ²McGill University, Gatineau, QC</p> |
| <p>7 QOL COMPARISON OF ACUTE SIDE EFFECTS FROM A HIGH DOSE RATE VERSUS LOW DOSE RATE PROSTATE BRACHYTHERAPY BOOST COMBINED WITH EXTERNAL BEAM RADIOTHERAPY Tracey Rose, Eleanor Garcia, Francois Bachand, David Kim, David Petrik, Ross Halperin, Juanita Crook; University of British Columbia, Kelowna, BC</p> | <p>13 WHO SHOULD BEAR THE COST OF CONVENIENCE? A COST-EFFECTIVENESS ANALYSIS COMPARING EXTERNAL BEAM AND BRACHYTHERAPY RADIOTHERAPY TECHNIQUES FOR EARLY STAGE BREAST CANCER Merrylee McGuffin¹, Thomas Merino², Brian Keller², Jean-Philippe Pignol³; ¹Sunnybrook Health Sciences Centre, Toronto, ON; ²University of Toronto, Toronto, ON; ³Erasmus MC: University Medical Centre Rotterdam, Rotterdam, Netherlands</p> |
| <p>8 EARLY TOXICITY IN A RANDOMIZED TRIAL OF TWO FRACTIONATION SCHEDULES FOR HIGH DOSE-RATE BRACHYTHERAPY AS MONOTHERAPY IN LOW AND INTERMEDIATE RISK PROSTATE CANCER Gerard Morton, Andrew Loblaw, Hans Chung, Merrylee McGuffin, Liying Zhang, Laura D'Alimonte, Ananth Ravi; University of Toronto, Toronto, ON</p> | <p>14 PROSTATE VOLUME DOWNSIZING AND TESTOSTERONE RECOVERY WITH DEGARELIX PRIOR TO BRACHYTHERAPY Jasbir Jaswal¹, Jim Rose², David Bowes³, David Petrik⁴, Francois Bachand⁴, Brent Parker⁴, Juanita Crook¹; ¹British Columbia Cancer Agency, Kelowna, BC; ²Cross Cancer Institute, Edmonton, AB; ³Dalhousie University, Halifax, NS; ⁴British Columbia Cancer Agency, Centre for the Southern Interior, Kelowna, BC</p> |
| <p>9 POST-IMPLANT DOSIMETRY FOR RECENT IMPLEMENTATION OF PERMANENT BREAST SEED IMPLANTS IN BRITISH COLUMBIA SHOWS A RAPID LEARNING CURVE Michelle Hilts¹, Deidre Batchelar¹, Daniel Morton², Juanita Crook¹; ¹British Columbia Cancer Agency, Southern Interior, Kelowna, BC; ²University of Victoria, Victoria, BC</p> | <p>15 LONG-TERM RESULTS OF INTERSTITIAL BRACHYTHERAPY FOR ACCELERATED PARTIAL-BREAST IRRADIATION Marc Gaudet¹, Jade Trudel Sabourin², Jonathan Nguyen³, Debbie Wright⁴, Doiron Annie⁴, Mathieu Pharand-Charbonneau⁴, Mustapha Chelfi⁴; ¹McGill University, Gatineau, QC; ²Université de Sherbrooke, Sherbrooke, QC; ³Université de Montréal, Montréal, QC; ⁴CSSS de Gatineau, Gatineau, QC</p> |
| <p>10 SALVAGE LOW DOSE RATE PERMANENT SEED BRACHYTHERAPY FOR LOCALLY RECURRENT PROSTATE CANCER: ASSOCIATION BETWEEN D90 AND LATE TOXICITY Jim Rose¹, Juanita Crook², Tom Pickles³, Mira Keyes³, W James Morris³; ¹Cross Cancer Centre, Edmonton, AB; ²British Columbia Cancer Agency, Kelowna, BC; ³British Columbia Cancer Agency, Vancouver, BC</p> | |

3:50-5:20 **ORAL SESSION 2 - HEAD AND NECK** *Columbia*

Moderators: Scott Bratman, Andrew Hope

OBJECTIVES: At the end of this session, the participants will be able to:

- hear about some exciting and interesting topics in the current landscape of head and neck cancer treatments, including the results of a Phase III NCIC multicentre clinical trial looking at standard chemotherapy and radiation versus accelerated radiation therapy with Panitumumab.

- | | |
|--|---|
| <p>16 A PHASE III MULTI-CENTRE RANDOMIZED TRIAL OF STANDARD FRACTIONATION RADIOTHERAPY WITH CONCURRENT CISPLATIN VERSUS ACCELERATED FRACTIONATION RADIOTHERAPY WITH PANITUMUMAB IN PATIENTS WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: NCIC CLINICAL TRIALS GROUP HN.6 TRIAL (NCT00820248) John Waldron¹, Lillian Siu¹, Binshu Chen², Eric Winquist³, Jim Wright⁴, Abdenour Nabid⁵, John Hay⁶, Jolie Ringash¹, Geoffrey Liu¹, TJ Fitzgerald⁷, George Shenouda⁸, Libni Eapen⁹, Andrew Pierce¹⁰, James Butler¹¹, Stephen Breen¹, Eric Chen¹, Timothy Childs², Alexander Montenegro², Wendy Parulekar², Brian O'Sullivan¹; ¹University of Toronto, Toronto, ON; ²Queen's University, Kingston, ON; ³University of Western Ontario, London, ON; ⁴McMaster University, Hamilton, ON; ⁵Universitaire de Sherbrooke, Sherbrooke, QC; ⁶University of British Columbia, Vancouver, BC; ⁷University of Massachusetts, Providence, RI, USA; ⁸McGill University, Montreal, QC; ⁹University of Ottawa, Ottawa, ON; ¹⁰Laurentian University, Sudbury, ON; ¹¹University of Winnipeg, Winnipeg, MB</p> | <p>20 PATIENTS WITH SQUAMOUS CELL CANCER OF NECK NODE(S) AND UNKNOWN PRIMARY SITE: WOULD STANDARDIZED WORK-UP EXPEDITE MANAGEMENT? Joanna Mackenzie¹, Kevin Martell¹, Warren Kerney², Harold Lau¹; ¹University of Calgary, Calgary, AB; ²Alberta Health Services, Calgary, AB</p> |
| <p>17 STROKE AFTER RADIOTHERAPY TO TREAT HEAD AND NECK CANCER - WHAT IS THE RISK? Erin Arthurs, Timothy Hanna, Khaled Zaza, Yingwei Peng, Stephen F Hall; Queen's University, Kingston, ON</p> | <p>21 METASTATIC RISK GROUPS IN HUMAN PAPILLOMAVIRUS-RELATED OROPHARYNGEAL CANCER TREATED WITH DEFINITIVE RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY Brian O'Sullivan, Shao Hui Huang, John Waldron, Susie Su, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Jolie Ringash, Aaron Hansen, David Goldstein, Li Tong, Bayardo Perez-Ordenez, Ilan Weinreb, Wei Xu; Princess Margaret Cancer Centre, Toronto, ON</p> |
| <p>18 VALIDATION OF METABOLIC TUMOUR VOLUME AS A PROGNOSTIC FACTOR FOR ORAL CAVITY SQUAMOUS CELL CARCINOMA Han Zhang¹, Hadi Seikaly¹, Jonathan T. Abele¹, Nhu-Tram Nguyen², Jeffrey R. Harris¹, Daniel A. O'Connell¹; ¹University of Alberta, Edmonton, AB; ²McMaster University, Hamilton, ON</p> | <p>22 RISK OF RELAPSE PROFILE IN HUMAN PAPILLOMAVIRUS-UNRELATED OROPHARYNGEAL CARCINOMA TREATED WITH DEFINITIVE RADIOTHERAPY WITH OR WITHOUT CHEMOTHERAPY Shao Hui Huang, John Waldron, Susie Su, Li Tong, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Jolie Ringash, Aaron Hansen, David Goldstein, Bayardo Perez-Ordenez, Ilan Weinreb, Wei Xu, Brian O'Sullivan; University of Toronto, Toronto, ON</p> |
| <p>19 POST-RADIOTHERAPY CERVICAL LYMPH NODE CALCIFICATION ON ITS OWN IS NOT PREDICTIVE FOR NECK RECURRENCE IN OROPHARYNGEAL CARCINOMA Shrinivas Rathod, Shao Hui Huang, John Waldron, John Kim, Eugene Yu, Li Tong, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, Jolie Ringash, Brian O'Sullivan; University of Toronto, Toronto, ON</p> | <p>23 COST-EFFECTIVENESS OF RADIATION THERAPY VS TRANS-ORAL ROBOTIC SURGERY FOR EARLY STAGE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA Danielle Rodin¹, Lisa Caulley², Emily Burger³, Jane Kim³, David Palma⁴, Stephanie Johnson-Obaseki², Brian O'Sullivan¹; ¹University of Toronto, Toronto, ON; ²University of Ottawa, Ottawa, ON; ³Harvard School of Public Health, Boston, MA, USA; ⁴London Regional Cancer Program, London, ON</p> |
| | <p>24 MAGNITUDE AND TIMING OF GTV RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND CONCURRENT CHEMO-RADIATION IN THE TREATMENT OF LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA Joshua Giambattista, Nevin McVicar, Monty Martin, Cheryl Ho, Benjamin Maas, John Hay, John Wu, Mira Keyes, Eric Berthelet; University of British Columbia, Vancouver, BC</p> |

3:50-5:20 **ORAL SESSION 3 – POPULATION SCIENCE AND HEALTH SCIENCES** *Okanagan*

Moderators: David Hodgson, Toni Barnes

OBJECTIVES: At the end of this session, the participants will be able to:

- learn about some very diverse and interesting topics affecting cancer patients and the radiation oncology team that treats them, including end of life, death at home, utilization and travel times, radiation wait times, quality of care indicators, and peer review practices.

25 **END-OF-LIFE HEALTH SERVICES UTILIZATION FOR PATIENTS WITH PROSTATE CANCER IN QUEBEC ACCORDING TO INITIAL TREATMENT** Fabio Cury, Armen Aprikian, Jason Hu, Marie Vanhuyse, Alice Dragomir; McGill University Health Centre, Montreal, QC

¹Cancer Centre of Southern Ontario, Kingston, ON; ²Queen's University, Kingston, ON; ³University of Toronto, Toronto, ON; ⁴Durham Regional Cancer Centre, Oshawa, ON; ⁵Cancer Care Ontario, Toronto, ON; ⁶Canadian Partnership Against Cancer, Toronto, ON; ⁷Pan-Canadian Peer Review Initiative Steering Committee, Cancer Care Ontario, Toronto, ON

26 **USING QUALITY IMPROVEMENT TOOLS TO ADDRESS RADIATION WAIT TIMES IN PATIENTS WITH HEAD AND NECK CANCERS** Julie Renaud¹, Jason Pantarotto², Miller MacPherson³; ¹The Ottawa Hospital, Ottawa, ON; ²University of Ottawa, Ottawa, ON; ³Ottawa Hospital Research Institute, Ottawa, ON

27 **QUANTIFYING THE RELATIONSHIP BETWEEN RADIATION THERAPY UTILIZATION AND TRAVEL TIME** Emma Liu¹, Scott Tyldesley¹, Pablo Santibanez¹, Martin Puterman², Leah Weber¹, Claire Ma¹, Antoine Saure², Ivo Olivotto³, Ross Halperin⁴, John French¹; ¹British Columbia Cancer Agency, Vancouver, BC; ²University of British Columbia, Vancouver, BC; ³University of Calgary, Calgary, BC; ⁴British Columbia Cancer Agency, Kelowna, BC

28 **A PAN-CANADIAN SURVEY OF PEER REVIEW PRACTICES IN RADIATION ONCOLOGY** Amanda Caissie¹, Paul Jugpal¹, Carol-Anne Davis¹, Helmut Hollenhorst¹, Jennifer O'Donnell², Julie Rouette², Gunita Mitera³, Michael Brundage²; ¹Dalhousie University, Saint John, NB; ²Queen's University, Kingston, ON; ³Canadian Partnership Against Cancer, Toronto, ON

29 **DETERMINANTS OF HOME DEATH IN CANCER PATIENTS, A POPULATION-BASED STUDY IN ONTARIO, CANADA** Hamid Raziee; University of Toronto, Toronto, ON

30 **THE PEER REVIEW OF RADICAL TREATMENT PLANS AND ITS ASSOCIATED OUTCOMES IN RADIATION ONCOLOGY PROGRAMS IN ONTARIO CANCER CENTRES** Michael Brundage¹, Julie Rouette², Sophie Foxcroft³, Margaret Hart⁴, Eric Gutierrez⁵, Lindsay Reddeman⁵, Jennifer O'Donnell², Gunita Mitera⁶, Padraig Warde⁴, Steering Committee⁷;

31 **RADIATION ONCOLOGY PEER REVIEW: THE FACILITATORS AND CHALLENGES TO IMPLEMENTING A PROGRAM OF PEER REVIEW** Margaret Hart¹, Sophie Foxcroft², Eric Gutierrez³, Jennifer O'Donnell⁴, Lindsay Reddeman³, Gunita Mitera⁵, Padraig Warde², Michael Brundage⁶; ¹Durham Regional Cancer Centre, Oshawa, ON; ²University of Toronto, Toronto, ON; ³Cancer Care Ontario, Toronto, ON; ⁴Queen's University, Kingston, ON; ⁵Canadian Partnership Against Cancer, Toronto, ON; ⁶On behalf of the Pan-Canadian Peer Review Initiative Steering Committee, Toronto, ON and the Cancer Care Ontario Radiation Treatment Program, Toronto, ON

32 **PAN-CANADIAN RADIOTHERAPY QUALITY OF CARE INDICATORS FOR INVASIVE BREAST CANCER** Lara Best¹, Catherine de Metz¹, Ivo Olivotto², Isabelle Roy³, Tim Whelan⁴, Julie Arsenault⁴, Michael Brundage¹; ¹Queen's University, Kingston, ON; ²University of Calgary, Calgary, AB; ³Laval University, Laval, QC; ⁴MacMaster University, Hamilton, ON

33 **ONCOLOGY PHYSICIAN ATTITUDES TOWARDS PATIENT AND FAMILY-CENTERED CARE** Timothy K Nguyen¹, Glenn Bauman¹, Christopher Watling², Karin Hahn¹; ¹London Regional Cancer Program, London, ON; ²Western University, London, ON



6:00-7:00 **The Pamela Catton Memorial Run/Walk for CROF**
Meet on the boardwalk at the back of the hotel at 5:45pm

7:00-10:00 **WELCOME RECEPTION** *Laurel Packinghouse 1304 Ellis Street (778) 478-0325*

FRIDAY SEPTEMBER 11, 2015

7:30-8:30 **REGISTRATION AND BREAKFAST**

8:30-8:45 **WELCOME AND INTRODUCTIONS**

8:45-9:45 **Gordon Richards Lecture** *Okanagan*

Introduction: Anthony Fyles

TARGETING CANCER AT THE BIOLOGY-TECHNOLOGY INTERFACE

Michael Milosevic

OBJECTIVES: At the end of this session, the participants will be able to:

- || understand the complementary nature of biological and anatomical tumor targeting;
- || discuss the opportunities and challenges associated with integrating biological and anatomical tumor targeting to improve the effectiveness of radiation treatment while maintaining quality and safety;
- || discuss the role of Canadian radiation oncologists as champions of new combined modality treatment strategies.

9:45-10:00 *Break*

10:00-11:00 **RESIDENT COMPETITION**

Moderator: Søren Bentzen

OBJECTIVES: At the end of this session, the participants will be able to understand the breast cancer risk associated with volume of radiation in Hodgkin Lymphoma, palliation options for bile duct obstruction, survival related to neutrophil counts in prostate cancer, outcomes and control of optic nerve meningioma, guideline adherence, and pattern of relapse and prognosis in cervical cancers.

34 A POPULATION-BASED ANALYSIS OF SECONDARY BREAST CANCER RISK ACCORDING TO RADIATION VOLUME IN WOMEN WITH HODGKIN LYMPHOMA

Jessica Conway¹, Joseph Connors², Tom Pickles²;

¹British Columbia Cancer Agency, Vancouver, BC;

²University of British Columbia, Vancouver, BC

35 INTRALUMINAL BRACHYTHERAPY: AN EFFECTIVE PALLIATION FOR CHOLANGIOCARCINOMA CAUSING BILE DUCT OBSTRUCTION? Nhu-Tram A. Nguyen,

Emilia Timotin, Robert Hunter, Ranjan K Sur;

McMaster University, Hamilton, ON

36 NEUTROPHIL COUNT IS ASSOCIATED WITH SURVIVAL IN LOCALIZED PROSTATE CANCER Houda

Bahig, Denis Soulières, Guila Delouya, Amal Nadiri,

Ariane Gagnon-Jacques, Paule Bodson-Clermont,

Daniel Taussky; Centre Hospitalier de l'Université de

Montréal, Montréal, QC

37 VISUAL OUTCOMES AND LOCAL CONTROL AFTER FRACTIONATED STEREOTACTIC RADIOTHERAPY FOR OPTIC NERVE SHEATH MENINGIOMA Sarah

Hamilton¹, Alan Nichol¹, Fred Hsu², Pauline Truong³,

Peter Dolman¹, Arthur Cheung⁴, Michael McKenzie¹,

Roy Ma¹; ¹British Columbia Cancer Agency, Vancouver,

BC; ²British Columbia Cancer Agency, Abbotsford, BC;

³British Columbia Cancer Agency, Victoria, BC; ⁴British

Columbia Cancer Agency, Surrey, BC

38 ASSESSING GUIDELINE ADHERENCE: REFERRAL PATTERNS OF POST-PROSTATECTOMY PATIENTS TO RADIATION ONCOLOGISTS Amandeep Taggar¹,

Majed Alghamdi¹, Derek Tilly², Xanthoula Kostaras²,

Marc Kerba¹, Michael Sia¹; ¹University of Calgary,

Calgary, AB; ²Alberta Cancer Board, Calgary, AB

39 DISTANT METASTASES IN LOCALLY ADVANCED CERVICAL CANCER: PATTERN OF RELAPSE AND PROGNOSTIC FACTORS – EARLY RESULTS FROM THE EMBRACE STUDY Israel Fortin¹, Ina

M. Jürgenliemk-Schulz², Umesh Mahanshetty³,

Christine Haie-Meder⁴, Peter Hoskin⁵, Barbara

Segedin⁶, Christian Kirisits⁷, Kari Tanderup⁸, Jacob

Christian Lindegaard⁸, Kathrin Kirchheiner⁷, Richard

Pötter⁷; ¹Centre hospitalier de l'université de Montréal

(CHUM), Montreal, QC; ²Utrecht University, Utrecht,

Netherlands; ³Tata Memorial Centre, Mumbai, India;

⁴Institut de Cancérologie Gustave Roussy, Paris, France;

⁵University College London, London, United Kingdom;

⁶Institute of Oncology Ljubljana, Ljubljana, Slovenia; ⁷Medical

University of Vienna, Vienna, Austria; ⁸Aarhus University

Hospital/Aarhus University, Aarhus, Denmark

11:00-12:00 FELLOW COMPETITION

Moderators: Michael Brundage, Michael McKenzie

OBJECTIVES: At the end of this session, the participants will be able to understand role of induction chemotherapy with TPF and radiation/chemotherapy in head and neck cancer, MRI guided brachytherapy and daily plan adaptation, results and toxicity of hypofractionated radiotherapy without hormones in intermediate risk prostate cancers, as well as long term outcomes of bicalutamide and dose escalated radiotherapy in intermediate risk prostate cancer, and weekly concomitant boosts during whole breast hypofractionated radiation therapy.

41 THE ROLE OF INDUCTION CHEMOTHERAPY WITH TPF AND RADIO-CHEMOTHERAPY FOR HEAD AND NECK CANCER: A META-ANALYSIS Edwin Boelke¹, Christiane Matuschek¹, Kai Kammers², Stephan Gripp¹, Wilfried Budach¹; ¹Heinrich Heine University, Dusseldorf, Germany; ²Johns Hopkins Bloomberg, Baltimore, MD, USA

42 IMPROVING THE EFFICIENCY OF MRI-GUIDED BRACHYTHERAPY FOR CERVICAL CANCER: IS DAILY PLAN ADAPTATION REQUIRED? Julia Skliarenko¹, Marco Carlone¹, Kathy Han¹, Akbar Beiki-Ardakani¹, Jette Borg¹, Jennifer Croke², Abdulmajeed Dayyat¹, Wilfred Levin¹, Lee Manchul¹, Alexandra Rink¹, Reem Ujaimi¹, Jason Xie¹, Anthony Fyles¹, Michael Milosevic¹; ¹University of Toronto, Toronto, ON; ²Dr. H. Bliss Murphy Cancer Centre, St John's, NL

43 HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY WITHOUT ANDROGEN DEPRIVATION FOR INTERMEDIATE RISK PROSTATE CANCER (IRPC): LONG TERM RESULTS AND TOXICITY ANALYSIS Osmar Barbosa Neto, Sergio Faria, Fabio Cury, Marc David, Marie Duclos, George Shenouda, Luis Souhami; McGill University, Montreal, QC

44 LONG TERM OUTCOMES OF A PHASE III STUDY OF BICALUTAMIDE HORMONE THERAPY WITH DOSE ESCALATED RADIOTHERAPY IN INTERMEDIATE RISK PROSTATE CANCER Andrew Mcpartlin, Rachel Glicksman, Melania Pintilie, Andrew Bayley, Robert Bristow, Peter Chung, Mary Gospodarowicz, Charles Catton, Michael Milosevic, Padraig Warde; University of Toronto, Toronto, ON

45 WEEKLY CONCOMITANT BOOST DURING WHOLE BREAST HYPOFRACTIONATED RADIOTHERAPY: A FEASIBILITY AND TOXICITY STUDY Ali Hosni¹, Eman Awad², Basel Refky², Ghada Ezzat Eladawi²; ¹University of Toronto, Toronto, ON; ²Mansoura University, Mansoura, Egypt

12:00-2:00 *Lunch Break*

12:00-1:00 *COMMITTEE MEMBER LUNCH*

1:00-1:45 **COMMITTEE MEETINGS**

2:00-3:00 ORAL SESSION 4 – APPLIED PHYSICS AND TECHNOLOGY *Skaha*

Moderators: Marie-Pierre Millette, George Shenouda

OBJECTIVES: At the end of this session, the participants will be able to understand VMAT interactive treatment planning in Head and Neck cancer, Liver cancer GTV and dynamic contrast enhanced CT scans, dosimetric impact of ACUROS XB on Lung SABR patients, quality assurance programs and SBRT in Lung cancer, vascular disorders induced by SRS in a rat brain measured by MRI, and the utility of MRI for prostate bed radiation therapy.

46 REAL-TIME INTERACTIVE TREATMENT PLANNING FOR HEAD AND NECK VMAT Quinn Matthews¹, Sally Smith¹, Ante Mestrovic¹, Wayne Beckham¹, Karl Otto²; ¹British Columbia Cancer Agency, Vancouver Island Centre, Victoria, BC; ²University of British Columbia, Vancouver, BC

47 DOES DYNAMIC CONTRAST ENHANCED CT AID GROSS TUMOUR VOLUME DELINEATION OF LIVER CANCERS Michael Lock¹, Nikolaj Jensen², Danielle Mulder², Barbara Fisher², Roman Kozak², Jeff Chen², Ting Yim-Lee², Eugene Wong²; ¹London Regional Cancer Centre, London, ON; ²Western University, Copenhagen, Denmark

48 DOSIMETRIC IMPACT OF THE NEW ECLIPSE ALGORITHM (ACUROS XB) ON LUNG SABR PATIENTS TREATED WITH THE VARIAN TRUEBEAM FLATTENING-FILTER-FREE MODE Derek Hyde¹, Tony Teke², Mathew Schmid¹; ¹University of British Columbia, Kelowna, BC; ²British Columbia Cancer Agency, Southern Interior, Kelowna, BC

- 49** **EARLY RESULTS OF A QUALITY ASSURANCE PROGRAM IN A RANDOMIZED TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR EARLY STAGE MEDICALLY INOPERABLE NON-SMALL CELL LUNG CANCER** Anand Swaminath¹, Marcin Wierzbicki¹, Jim Wright¹, Theodoros Tsakiridis¹, Kathryn Cline², Cathy Bucci¹, Orest Ostapiak¹, Jim Julian², Sameer Parpia², Tim Whelan¹; ¹Juravinski Cancer Centre, Hamilton, ON; ²McMaster University, Hamilton, ON

- 51** **IS MAGNETIC RESONANCE IMAGING FOR PROSTATE BED RADIOTHERAPY PLANNING USEFUL?** Maroie Barkati, Guila Delouya, Dany Simard, Daniel Taussky; Centre Hospitalier de l'Université de Montréal, Montreal, QC

- 210** **A QUALITY IMPROVEMENT EVALUATION OF EVOLVING TECHNOLOGIES IN LIVER SBRT** Darby Erler¹, Renee Korol¹, William Chu², Nikki Deegan³, Brenda Schultz³, Hans Chung²; ¹Sunnybrook Odette Cancer Centre, Toronto, ON; ²University of Toronto, Toronto, ON; ³Toronto, ON

2:00-3:00 **ORAL SESSION 5 – LUNG** Vaseaux/Kootenay

Moderators: Anthony Brade, George Rodrigues

OBJECTIVES: At the end of this session, the participants will be able to:

- learn about overall survival following SBRT using the Amsterdam Prognostic Model, outcomes in stage 3 NSCLC patients treated with surgery following concurrent neoadjuvant chemoradiation, intrafractional target shift during Lung SBRT, radiation pneumonitis following SBRT in patients with pulmonary fibrosis, histology and tumour control probability estimates, and esophageal sparing techniques in concurrent chemotherapy and radiation in thoracic malignancies.

- 52** **PREDICTING OVERALL SURVIVAL FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY IN EARLY-STAGE LUNG CANCER: DEVELOPMENT AND EXTERNAL VALIDATION OF THE AMSTERDAM PROGNOSTIC MODEL** Alex Louie¹, Cornelis Haasbeek², Sahar Mokhles³, George Rodrigues¹, Kevin Stephens⁴, Frank Lagerwaard², David Palma¹, Gregory Videtic⁴, Andrew Warner¹, Johanna Takkenberg³, Chandana Reddy⁴, Neil Woody⁴, Ben Slotman², Suresh Senan²; ¹London Regional Cancer Program, London, ON; ²VU University, Amsterdam, Netherlands; ³Erasmus Medical Center, Rotterdam, Netherlands; ⁴Cleveland Clinic, Cleveland, OH, USA

- 54** **INTRAFACTIONAL TARGET SHIFT DURING LUNG STEREOTACTIC ABLATIVE BODY RADIATION THERAPY** James Sidney, Alanah Bergman, Mitchell Liu, Adrian White, Yvonne Zheng; British Columbia Cancer Agency, Vancouver, BC

- 55** **SEVERE RADIATION PNEUMONITIS AFTER LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY IN PATIENTS WITH PULMONARY FIBROSIS** Houba Bahig, Edith Fillion, Toni Vu, Louise Lambert, Jean Chalaoui, David Roberge, Dominique Mathieu, Dominic Beliveau-Nadeau, Michel Gagnon, Bernard Fortin, Marie-Pierre Campeau; Centre Hospitalier de l'Université de Montréal, Montreal, QC

- 53** **OUTCOMES IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER TREATED WITH NEOADJUVANT CONCURRENT CHEMOTHERAPY AND RADIOTHERAPY FOLLOWED BY SURGICAL RESECTION** Vivian Yau¹, Meredith Giuliani¹, Olive Wong², Lisa Le², Gail Darling¹, Frances Shepherd¹, Anthony Brade¹, John Cho¹, Alexander Sun¹, Andrea Bezjak¹, Andrew Hope¹; ¹University of Toronto, Toronto, ON; ²University Health Network, Toronto, ON

- 56** **RADIOTHERAPY TUMOUR CONTROL PROBABILITY ESTIMATES BASED ON HISTOLOGY FOR STAGE I NON-SMALL CELL LUNG CANCER** Oliver Holmes, Daniel La Russa, Graham Cook, Robert MacRae, Peter Cross, Jason R. Pantarotto; University of Ottawa, Ottawa, ON



photo courtesy of Mission Hill Winery.

2:00-3:00 **ORAL SESSION 6 – CNS AND RADIOSURGERY** *Okanagan*

Moderators: Thierry Muanza, Bassam Abdulkarim

OBJECTIVES: At the end of this session, the participants will be able to:

- || hear about vascular disorders measurements in the rat brain following SRS, a Phase II clinical trial assessing fractionated simultaneous in-field boost in brain oligometastases, referral patterns and outcomes of atypical meningioma patients, treated with and without radiation following surgery, benefit of repeat surgery in GBM patients in a single institution, survival of elderly patients with GBM with and without treatment, and treatment of malignant gliomas with a novel molecule, ZRBA1, a unique radiosensitizer.

58 VASCULAR DISORDERS MEASUREMENTS IN THE RAT BRAIN FOLLOWING TARGETED SRS USING NOVEL PRECISE GAMMA KNIFE IRRADIATION METHOD

Julie Constanzo, Laurence Masson-Côté, Mathieu Guillot, Luc Tremblay, Martin Lepage, Benoit Paquette; *Université de Sherbrooke, Sherbrooke, QC*

59 A PHASE II MULTI-INSTITUTIONAL CLINICAL TRIAL ASSESSING FRACTIONATED SIMULTANEOUS IN-FIELD BOOST RADIOTHERAPY FOR BRAIN OLIGOMETASTASES

George Rodrigues¹, Slav Yartsev¹, David Roberge², Robert MacRae³, Wilson Roa⁴, Valerie Panet-Raymond⁵, Laura Masucci², Brian Yaremko¹, David D'Souza¹, David Palma¹, Tracy Sexton¹, Edward Yu¹, Jason R Pantarotto³, Belal Ahmad¹, Barbara Fisher¹, A Rashid Dar¹, Carole Lambert², Gregory Pond⁶, Keng Yeow Tay¹, Glenn Bauman¹; ¹London Health Sciences Centre, London, ON; ²Centre Hospitalier de l'Université de Montréal, Montreal, QC; ³University of Ottawa, Ottawa, ON; ⁴Cross Cancer Institute, Edmonton, ON; ⁵McGill University Health Centre, Montreal, QC; ⁶McMaster University, Hamilton, ON

60 REFERRAL PATTERNS AND OUTCOMES OF ATYPICAL MENINGIOMA PATIENTS TREATED WITH SURGERY WITH AND WITHOUT RADIOTHERAPY

Maged Alghamdi, Haocheng Li, John Kelly, Jay Easaw, Rob Nordal, Gerald Lim; *University of Calgary, Calgary, AB*

61 BENEFITS OF REPEAT SURGERY FOR RECURRENT GLIOBLASTOMA: RESULTS FROM A SINGLE INSTITUTION

Melissa Azoulay¹, George Shenouda¹, Kevin Petrecca², Ayman Oweida¹, Fabiano Santos¹, Suganthi Jeyaganth¹, Bassam Abdulkarim¹; ¹McGill University Health Centre, Montreal, QC; ²Montreal Neurological Hospital, Montreal, QC

62 GLIOBLASTOMA IN ELDERLY PATIENTS: SURVIVAL OUTCOMES WITH AND WITHOUT TREATMENT

Derek Tsang¹, Luluel Khan¹, James Perry¹, Hany Soliman¹, Arjun Sahgal¹, Julia Keith¹, Todd Mainprize¹, Sunit Das¹, Liying Zhang², May Tsao¹; ¹University of Toronto, Toronto, ON; ²MacroStat, Inc., Richmond Hill, ON

63 NOVEL BINARY MOLECULE, ZRBA1, AS A UNIQUE MGMT INDEPENDENT RADIOSENSITIZER TO TREAT MALIGNANT GLIOMAS

Thierry Muanza, Slawomir Kumala, Mitra Heravi, Hamed Bekerat, Mohamed S. Sadr, Rolando Del Maestro, Bertrand Jean-Claude; *McGill University, Montréal, QC*

3:00-4:00 **Jean Roy Lecture** *Okanagan*

Moderators: Ross Halperin, Marc Gaudet

17 YEARS OF PROSTATE BRACHYTHERAPY IN BC, FROM LUNCH WITH JEAN ROY TO THE FRONT PAGE OF THE GUARDIAN *Mira Keyes*

OBJECTIVES: during this session, participants will:

- || review the lessons learned from Prostate Brachytherapy about long term outcomes and biology of prostate cancer
- || outline the lessons yet to be learned in multimodality, and multidisciplinary treatment of prostate cancer
- || outline critical components necessary for success of a large clinical program

4:00-5:30 **ANNUAL GENERAL MEETING** *Okanagan*

7:00 **Dinner & Awards Ceremony**

Mission Hill Winery, 1730 Mission Hill Road (250) 768-7611

Transportation provided. Meet in lobby at 6:20pm.

SATURDAY, SEPTEMBER 12, 2015

7:45-8:30 **REGISTRATION AND BREAKFAST**

8:30-10:00 **ORAL SESSION 7 – GU CANCER** *Shuswap*

Moderators: Andrew Loblaw, Francois Bachand

OBJECTIVES: At the end of this session, the participants will be able to:

■ hear about intra-operative planned LDR brachytherapy and biochemical failure in prostate cancer, the Patriot trial study of SBRT prostate treatment times, 125 I Brachytherapy as solo treatment in high intermediate risk prostate cancer, MRI guided HDR brachytherapy boost in prostate cancer, late relapses in seminoma surveillance, declining Radiation Oncology referral rates in Alberta, prep or not to prep, late GU toxicity and quadrant dosimetry following prostate brachytherapy, and quality of life and toxicity outcomes following salvage HDR prostate brachytherapy.

64 NO DIFFERENCE IN BIOCHEMICAL FAILURE IN LOW AND INTERMEDIATE RISK PROSTATE CANCER PATIENTS AFTER INTRA-OPERATIVELY PLANNED LDR BRACHYTHERAPY Amandeep Taggar, Kevin Martell, Steve Angyal, Michael Sia, Siraj Husain; University of Calgary, Calgary, AB

65 PATRIOT TRIAL: RANDOMIZED PHASE II STUDY OF PROSTATE STEREOTACTIC BODY RADIOTHERAPY COMPARING 11 VERSUS 29 DAYS OVERALL TREATMENT TIME Harvey Quon¹, Aldrich Ong¹, Patrick Cheung², William Chu², Hans Chung², Danny Vesprini², Amit Chowdhury¹, Dilip Panjwani³, Geordi Pang⁴, Renee Korol⁴, Melanie Davidson⁴, Ananth Ravi², Boyd McCurdy⁵, Liying Zhang⁴, Oliver Buche⁵, Alexandre Mamedo⁴, Andrea Deabre⁴, Elizabeth Lylyk⁵, Andrew Loblaw²; ¹University of Manitoba, Winnipeg, MB; ²University of Toronto, Toronto, ON; ³University of British Columbia, Abbotsford, BC; ⁴Sunnybrook Health Sciences Centre, Toronto, ON; ⁵CancerCare Manitoba, Winnipeg, MB

66 CAN HIGH-INTERMEDIATE RISK PROSTATE CANCER BE TREATED ADEQUATELY WITH 125 I BRACHYTHERAPY ALONE? Tom Pickles, W James Morris, Juanita Crook, Mira Keyes; University of British Columbia, Vancouver, BC

67 MRI-GUIDED HDR BRACHYTHERAPY BOOST FOR PROSTATE CANCER Jure Murgic, Peter Chung, Andrew Bayley, Saibishkumar Elantholi Parameswaran, Padraig Warde, Charles Catton, Ana Simeonov, Jessamine Abed, Alexandra Rink, Cynthia Ménard; University of Toronto, Toronto, ON

68 LATE RELAPSE IN SEMINOMA SURVEILLANCE: EFFECT ON RELAPSE PATTERN AND CLINICAL OUTCOMES Ali Hosni, Padraig Warde, Philippe Bedard, Michael Jewett, Robert Hamilton, Malcolm Moore, Roger Huang, Martin O'Malley, Joan Sweet, Peter Chung; University of Toronto, Toronto, ON

69 A SLIPPERY SLOPE? DECLINING RADIATION ONCOLOGY REFERRAL RATES IN ALBERTA FOR HIGH RISK PROSTATE CANCER BETWEEN 2005 AND 2012 Majed Alghamdi¹, Amandeep Taggar¹, Mark Kerba¹, Derek Tilley², Xanthoula Kostaras², Michael Sia¹; ¹University of Calgary, Calgary, AB; ²Alberta Health Services, Calgary, AB

70 TO PREP OR NOT TO PREP: THAT IS THE QUESTION Merrylee McGuffin¹, Naila Devji¹, Lyann Kehoe², Anne Carty¹, Steve Russell¹, Lisa Di Prospero³, Farnoosh Hadizad¹, Carlo DeAngelis³, Danny Vesprini³, Laura D'Alimonte¹; ¹Sunnybrook Health Sciences Centre, Toronto, ON; ²The Ottawa Hospital, Ottawa, ON; ³University of Toronto, Toronto, ON

71 REGIONAL QUADRANT DOSIMETRY AND LATE GENITOURINARY TOXICITY AFTER LOW DOSE RATE PROSTATE BRACHYTHERAPY Sarah Hamilton, Mira Keyes, Veronika Moravan, Ingrid Spadinger, W James Morris; British Columbia Cancer Agency, Vancouver, BC

72 PRELIMINARY QUALITY OF LIFE (QOL) AND TOXICITY OUTCOMES OF A PILOT STUDY OF FOCAL SALVAGE HIGH DOSE RATE (HDR) PROSTATE BRACHYTHERAPY IN PATIENTS WITH LOCAL RECURRENCE AFTER DEFINITIVE EXTERNAL-BEAM RADIOTHERAPY (XRT) Hans Chung, Laura D'Alimonte, Andrew Loblaw, Ananth Ravi, Matt Wronski, Melanie Davidson, Masoom Haider, Gerard Morton; University of Toronto, Toronto, ON

8:30-10:00 **ORAL SESSION 8 – BREAST AND EDUCATION** Pennask/Skeena

Moderators: Meredith Giuliani, Paris Ingledew-Gfeller

OBJECTIVES: At the end of this session, the participants will be able to:

- appreciate the clinical specialist therapist role in rapid breast radiation delivery, hypofractionated radiation therapy for DCIS post op, standardization/reproducibility of partial breast seed implant and patient set up, a systemic review of ablative therapy for metastatic breast cancer, pretreatment review of radiation oncology breast cancer rounds in real time, patient reported outcomes 5 years after breast cancer treatment, healthcare cost impact in omission of radiation therapy in low risk luminal A breast cancer, dedicated instruction in anatomy, radiation, contouring and resident proficiency, online learning resources and oncology undergraduate medical education, and interprofessional teamwork.

73 BUILDING A NEW MODEL OF CARE FOR RAPID BREAST RADIOTHERAPY DELIVERY: EVALUATION OF THE CLINICAL SPECIALIST RADIATION THERAPIST ROLE WITHIN A MULTIDISCIPLINARY TEAM Grace Lee, Robert Dinniwel, Fei-Fei Liu, Anthony Fyles, Kathy Han, Tatiana Conrad, Wilfred Levin, Caroline Chung, Andrea Marshall, Thomas Purdie, Anne Koch; Princess Margaret Cancer Centre, Toronto, ON

74 USE OF HYPOFRACTIONATION SCHEDULE FOR POST LUMPECTOMY RADIATION THERAPY OF DUCTAL CARCINOMA *IN SITU* Naghmeh Isfahanian, Thuraya AlHajri, Horia Marginean, Jean-Michel Caudrelier; The Ottawa Hospital Regional Cancer Centre, Ottawa, ON

75 INCREASING THE STANDARDIZATION AND REPRODUCIBILITY OF PARTIAL BREAST SEED IMPLANT PATIENT SET UP Deidre Batchelar, Michelle Hilts, Tracey Rose, Michelle Brandel, Bart Robertson, Eleanor Garcia, Janet Yanchuck, Juanita Crook; British Columbia Cancer Agency, Kelowna, BC

76 ABLATIVE THERAPY FOR METASTATIC BREAST CANCER – A SYSTEMATIC REVIEW Michael Kucharczyk, Anand Swaminath; McMaster University, Hamilton, ON

77 APPLYING A REAL-TIME PRETREATMENT REVIEW OF RADIATION ONCOLOGY BREAST CANCER ROUNDS: AUTOMATED QUALITY ASSURANCE RESULTS Aisling Barry, Claudio Sole, Chris McIntosh, Thomas Purdie, Anne Koch; Princess Margaret Cancer Centre, Toronto, ON

78 ASSESSMENT OF PATIENT REPORTED OUTCOME QUESTIONS IN BREAST CANCER PATIENTS 5 YEARS AFTER ADJUVANT BREAST RADIOTHERAPY Robert Olson¹, Josh Powers², Justin Glazier³, Lindsay Mathews¹, Manpreet Tiwana¹; ¹British Columbia Cancer Agency, Centre for the North, Prince George, BC; ²University of Northern British Columbia, Prince George, BC; ³Royal College of Surgeons in Ireland, Dublin, Ireland

229 OMISSION OF BREAST RADIOTHERAPY IN LOW-RISK LUMINAL A BREAST CANCER: IMPACT ON CANADIAN HEALTH CARE COSTS Kathy Han¹, Mei Ling Yap¹, Jean Yong², Nicole Mittmann³, Jeffrey Hoch², Anthony Fyles¹, Padraig Warde¹, Eric Gutierrez⁴, Timothy Lymberiou¹, Sophie Foxcroft¹, Fei-Fei Liu¹; ¹Princess Margaret Cancer Centre, Toronto, ON; ²St. Michael's Hospital, Toronto, ON; ³University of Toronto, Toronto, ON; ⁴Cancer Care Ontario, Toronto, ON

79 DOES DEDICATED INSTRUCTION IN ANATOMY, RADIOLOGY AND CONTOURING IMPROVE PROFICIENCY IN RADIATION ONCOLOGY? AN ANALYSIS OF >50 RESIDENTS Jasbir Jaswal¹, Leah D'Souza², Sonya Van Nuland², Marjorie Johnson², Katherine Willmore², Kevin Fung³, Anthony Nichols⁴, Mark Landis⁴, KengYeow Tay⁴, Zahra Kassam⁵, Eric Leung⁶, David D'Souza⁵, Andrew Warner⁵, Tracy Sexton⁴, David Palma⁵; ¹British Columbia Cancer Agency, Kelowna, BC; ²Western University, London, ON; ³Victoria Hospital, London, ON; ⁴London Health Sciences Centre, London, ON; ⁵St. Joseph's Health Care, London, ON; ⁶Odette Cancer Centre, Toronto, ON

80 HELPING TO BRIDGE THE GAP: THE DEVELOPMENT OF ONLINE LEARNING RESOURCES TO SUPPLEMENT ONCOLOGY UNDERGRADUATE MEDICAL EDUCATION Paris-Ann Ingledew¹, Sarah Hamilton², Pretty Verma², Elana Thau³, Allison Lee², Leo Lai², Joanne Tseng²; ¹British Columbia Cancer Agency, Fraser Valley, Surrey, BC; ²University of British Columbia, Vancouver, BC; ³University of Toronto, Toronto, ON

81 BREAKING DOWN SILOS AND BUILDING UP ROBUST SYSTEMS: AN INTERPROFESSIONAL TEAM AT WORK! Brian Liszewski¹, Jackie Ezezika², Eirena Calabrese², Alrene Court², Glen Gonzales², Yoo-Joung Ko², Colin Myers², Mark Pasetka², Stephen Russell², Yee Ung²; ¹Odette Cancer Centre, Toronto, ON; ²University of Toronto, Toronto, ON

8:30-10:00 **ORAL SESSION 9 – VARIETY PACK** *Okanagan*

Moderators: Derek Wilke, Anand Swaminath

OBJECTIVES: At the end of this session, the participants will be able to:

- understand the effects of seroma definition using 3D ultrasound technology in seed brachytherapy, secondary lung cancer primaries after head and neck cancer, outcomes in Stage I-II diffuse large B-cell lymphoma with extradural involvement, provincial consensus guidelines in lung SBRT prescribing, optimization of atlas-based auto-segmentation of parotid glands using an in-house atlas library in head and neck planning, *Do Not Resuscitate* discussions, prostate SABR and hematochezia predicted by treatment volume and rectal dosimetry, resource implications and rapid access radiotherapy, and a review of anal cancers.

- | | |
|---|---|
| <p>82 EFFECTS OF SEROMA DEFINITION USING 3D ULTRASOUND ON PERMANENT BREAST SEED IMPLANT BRACHYTHERAPY Daniel Morton¹, Michelle Hilts², Deidre Batchelar¹, Tanya Berrang¹, Juanita Crook²; ¹University of Victoria, Kelowna, BC; ²British Columbia Cancer Agency, Kelowna, BC</p> | <p>86 PERFORMANCE OPTIMIZATION OF ATLAS-BASED AUTO-SEGMENTATION OF PAROTID GLANDS FOR HEAD AND NECK RADIOTHERAPY PLANNING USING AN IN-HOUSE ATLAS LIBRARY Eman Khawandanh, Cheryl Duzenli, Haley Clark, Jonn Wu, Steven Thomas, Eric Berthelet; University of British Columbia, Vancouver, BC</p> |
| <p>83 SECOND PRIMARY LUNG CANCER FOLLOWING HEAD AND NECK CANCER: A POPULATION BASED STUDY OF TREATMENT AND SURVIVAL IN THE NETHERLANDS Alex Louie¹, Cornelis Haasbeek², Ronald Damhuis², Danielle Rodin³, Ben Slotman², Suresh Senan²; ¹London Regional Cancer Program, London, ON; ²VU University, Amsterdam, Netherlands; ³University of Toronto, Toronto, ON</p> | <p>87 DO NOT RESUSCITATE DISCUSSIONS - A PROSPECTIVE STUDY ON THE PERCEPTIONS OF PATIENTS, CARE GIVERS AND HEALTH CARE PROVIDERS IN A MULTIDISCIPLINARY LUNG CANCER CLINIC William Hunter, Naseer Ahmed, Michelle Lobchuk, Pam Johnston, Zoann Nugent, Ankur Sharma, Shahida Ahmed, Jeff Sisler; University of Manitoba, Winnipeg, MB</p> |
| <p>85 PROVINCIAL CONSENSUS GUIDELINES IMPROVED LUNG SBRT PRESCRIBING CONSISTENCY Sarah Baker¹, Ivo Olivetto², Richie Sinha², Danielle Bru², Trevor Campbell², Sunita Ghosh¹, Elizabeth Kurien², Hongwei Liu², Brad Murray¹, Rufus Scrimger¹, Zsolt Gabos¹; ¹University of Alberta, Edmonton, AB; ²University of Calgary, Calgary, BC</p> | <p>88 RADIOTHERAPY TREATMENT VOLUME AND RECTAL DOSIMETRY PREDICT CLINICALLY SIGNIFICANT HEMATOCHESIA IN GANTRY BASED FIVE FRACTION PROSTATE SABR Hima Bindu Musunuru¹, Melanie Davidson¹, Patrick Cheung¹, Andrea D'eabreu¹, Liying Zhang¹, Laura D'Alimonte², Ananth Ravi², Joelle Helou¹, Alexander Mamedov¹, Andrew Loblaw¹; ¹University of Toronto, Toronto, ON; ²Odette Cancer Centre, Toronto, ON</p> |
| <p>222 BIOCHEMICAL RESPONSE OF LOCALIZED LOW AND LOW-INTERMEDIATE RISK PROSTATE CANCER (PRCA) TO STEREOTACTIC BODY RADIOTHERAPY (SBRT). COMPARISON WITH CONVENTIONAL FRACTIONATION EXTERNAL BEAM RADIOTHERAPY (CF-EBRT) Joanna Laba¹, Gregory Pond², Michael Kucharczyk¹, Laura Zychla¹, Ian Dayes¹, Tom Corbett¹, Malti Patel¹, Himu Lukka¹, Theodoros Tsakiridis¹; ¹Juravinski Cancer Centre, Hamilton, ON; ²Ontario Clinical Oncology Group, Hamilton, ON</p> | <p>89 RESOURCE IMPLICATIONS OF A RAPID ACCESS RADIOTHERAPY PROGRAM David Hoegler, Tracey Rose; British Columbia Cancer Agency, Kelowna, BC</p> |
| | <p>90 REVIEW OF 173 ANAL CANCERS IN A SINGLE INSTITUTION Laval Grimard¹, Chandni Jain², Saif Al-Thaqfi³, Yuhui Xu⁴, Rakesh Goel¹; ¹The Ottawa Hospital Cancer Centre, Ottawa, ON; ²University of Ottawa, Ottawa, ON; ³King Abdulaziz Medical City National Guard, Riyadh, Saudi Arabia; ⁴The Ottawa Hospital Research Institute, Ottawa, ON</p> |

10:00-10:15 *GRAB AND GO BREAK*

10:15-11:45 **CONCURRENT WORKSHOPS**

Workshop 1 *Shuswap*

COMPETENCY-BASED EDUCATION IN RADIATION MEDICINE

Meredith Giuliani, Caitlin Gillan, Emily Milne, Paris-Ann Ingledew, Andrea McNiven, Nicole Harnett

OBJECTIVES: At the end of this session, the participants will be able to:

- || demonstrate an understanding of the context and rationale for a competency-based approach to health professional clinical education;
- || identify opportunities and challenges related to implementation of competency-based approach to education;
- || identify potential strategies to facilitate teaching and assessment in competency-based education e.g. eLearning, simulation, and the concept of the inverted classroom;
- || demonstrate an appreciation of educational resources and tools that may be use in their own setting to maximize efficiency and educational outcomes.

Workshop 2 *Pennask/Skeena*

RADIATION ONCOLOGY PEER REVIEW: "TIPS", "TRICKS", "TRAPS", AND "TRENDS" FROM THE PAN-CANADIAN PEER REVIEW INITIATIVE

Michael Brundage, Gunita Mitera, Margaret Hart, Amanda Caissie

OBJECTIVES: At the end of this session, the participants will be able to:

- || understand the rationale and extent of current peer review activities;
- || understand barriers to peer review (e.g., medical-legal or operational concerns) and how these can be addressed effectively;
- || have tools and practical strategies on how to standardize, improve, and/or expand peer review activities in practice.

Workshop 3 *Okanagan*

ADVANCED COURSE ON PELVIC ANATOMY AND CONTOURING; PELVIC IMRT, GYNE AND GU IMAGE-GUIDED BRACHYTHERAPY SPEAKERS

Juanita Crook, Francois Bachand, Jasbir Jaswal

OBJECTIVES: At the end of this session, the participants will be able to:

- || identify the GU and GYN pelvic anatomy on CT-scan, MRI and Ultrasound;
- || delineate clinical target volumes (CTV) used for GU and GYN pelvic irradiation;
- || identify anatomy and target volumes on CT, MRI and Ultrasound for prostate brachytherapy;
- || delineate GTV, HR-CTV and IR-CTV on MRI for cervical brachytherapy.

Workshop 4 *Vaseaux/Kootenay*

THE CANADIAN NATIONAL SYSTEM FOR INCIDENT REPORTING IN RADIATION TREATMENT (NSIR-RT)

Michael Milosevic, Jordan Hunt, Carol-Anne Davis

OBJECTIVES: At the end of this session, the participants will be able to:

- || gain an understanding of how NSIR-RT was developed;
- || view the beta system live and learn how to be involved in the pilot;
- || learn how to classify incidents using the live beta system with real-time feedback from system developers and peers.

Workshop 5 *Chilcotin*

CONVERSATIONS ABOUT READINESS FOR END-OF-LIFE (CARE)

Michael McKenzie, Gillian Fyles, Carole Robinson

OBJECTIVES: At the end of this session, the participants will be able to:

- || understand the importance of conducting goals of care discussions with cancer patients within 1 year of the end of life and their families, and the resulting advantages both for them and physicians and other health care professionals;
- || better predict the life span remaining for a patient with advanced cancer and therefore when to have these discussions;
- || know some tips that are enormously helpful in conducting these discussions.

Workshop 6 *Cascade/Cassiar*

CREATING A PAN-CANADIAN RADIATION ONCOLOGY TRIALS NETWORK

Bassam Abdulkarim, Theodoros Tsakiridis

OBJECTIVES: At the end of this session, the participants will be able to:

- || review of existing Phase I and II radiotherapy trials in Canada;
- || review the potential benefits of developing a radiotherapy trials network;
- || identify obstacles in conducting local and national radiotherapy trials.

11:50-12:50 **REVIEWER'S CHOICE** Okanagan

Moderators: Fabio Cury, Gunita Mittra

OBJECTIVES: At the end of this session, the participants will be able to:

■ learn about SBRT for inoperable liver tumours, the role of PETCT in locally advanced cervical cancer decisions, mission creep: extension of the radiation oncology clinical work week, a randomized trial of bicalutamide and dutasteride versus LHRH agonists for prostate volume reduction prior to brachytherapy, bio/accelerated radiotherapy and quality of life compared to conventional chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the head and neck, in the NCIC HN.6 Phase III trial, and recursive partitioning analysis to predict survival post-biochemical failure in prostate cancer.

- 91 STEREOTACTIC BODY RADIOTHERAPY FOR INOPERABLE LIVER TUMOURS: RESULTS FROM A SINGLE INSTITUTIONAL EXPERIENCE ON SBRT** Hussam Hijazi¹, Marie-Pierre Campeau², Réal Lapointe², David Roberge², David Donath², Franck Vandenbroucke-Menu², Gabriel Chan², Alexis Bujold², Daniel Taussky², Kerianne Boulva²; Guila Delouya³; ¹King Abdulaziz University Hospital, Jeddah, Saudi Arabia; ²Université de Montréal, Montreal, QC; ³CHUM-Hôpital Notre-Dame, Montreal, QC,

- 92 THE ROLE OF PET-CT IN TREATMENT DECISION MAKING FOR WOMEN WITH LOCALLY ADVANCED CERVICAL CANCER** Anthony Fyles¹, Lorraine Elit², Chu-Shu Gu², Gregory Pond², David D'Souza³, Rajiv Samant⁴, Margaret Anthes⁵, Gillian Thomas¹, Marc Fillion⁶, Julie Arsenault⁷, Ian Dayes⁷, Timothy Whelan⁶, Karen Gulenchyn⁷, Mark Levine⁸; ¹University of Toronto, Toronto, ON; ²McMaster University, Hamilton, ON; ³London Regional Cancer Program, London, ON; ⁴Ottawa Hospital Cancer Centre, Ottawa, ON; ⁵Thunder Bay Regional Cancer Centre, Thunder Bay, ON; ⁶Ontario Clinical Oncology Group, Hamilton, ON; ⁷Hamilton Health Sciences, Hamilton, ON; ⁸Cancer Care Ontario, Hamilton, ON

- 93 MISSION CREEP: EXTENSION OF THE RADIATION ONCOLOGY CLINICAL WORK WEEK IN A LARGE CANADIAN ACADEMIC INSTITUTION** Jason Pantarotto¹, Julie Renaud², Robert MacRae¹, Miller MacPherson²; ¹University of Ottawa, Ottawa, ON; ²The Ottawa Hospital Research Institute, Ottawa, ON

- 94 RANDOMIZED TRIAL OF BICALUTAMIDE AND DUTASTERIDE VERSUS LHRH AGONISTS FOR PROSTATE VOLUME REDUCTION PRIOR TO I-125 PERMANENT IMPLANT BRACHYTHERAPY FOR PROSTATE CANCER** Marc Gaudet¹, Eric Vigneault², William Foster², Francois Meyer², Andre-Guy Martin²; ¹McGill University, Gatineau, QC; ²Université Laval, Quebec, QC

- 95 BIO/ACCELERATED RADIOTHERAPY DOES NOT DURABLY IMPROVE QUALITY OF LIFE (QOL) AS COMPARED WITH CONVENTIONAL CHEMORADIOTHERAPY FOR LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (LA-SCCHN): NCIC-CTG HN.6 PHASE III RANDOMIZED TRIAL** Jolie Ringash¹, John Waldron¹, Lillian Siu¹, Rosemary Martino¹, Eric Winquist², Jim Wright³, Abdenour Nabid⁴, John Hay⁵, Alex Hammond², Khalil Sultanem⁶, Sebastien Hotte³, Carson Leong⁷, Ali Abdel Halim El-Gayed⁸, Farah Naz⁹, Kevin Ramchandrar¹⁰, Tim Owen¹¹, Alexander Montenegro¹², Brian O'Sullivan¹, Bingshu Chen¹², Wendy Parulekar¹²; ¹University of Toronto, Toronto, ON; ²London Health Sciences Centre, London, ON; ³Juravinski Cancer Centre, Hamilton, ON; ⁴Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC; ⁵British Columbia Cancer Agency, Vancouver, BC; ⁶McGill University, Montreal, QC; ⁷British Columbia Cancer Agency, Fraser Valley Centre, Fraser Valley, BC; ⁸Saskatoon Cancer Centre, Saskatoon, SK; ⁹Horizon Health Network - Saint John Regional Hospital, Saint John, NB; ¹⁰Northwestern Ontario Regional Cancer Care, Thunder Bay, ON; ¹¹Cancer Centre of Southeast Ontario, Kingston, ON; ¹²NCIC Clinical Trials Group, Cancer Research Institute, Queen's University, Kingston, ON

- 96 POST-BIOCHEMICAL FAILURE RISK STRATIFICATION TO PREDICT SURVIVAL IN PROSTATE CANCER: A RECURSIVE PARTITIONING ANALYSIS** George Rodrigues¹, Tara Wang¹, Andrew Warner¹, Tom Pickles², Juanita Crook³, Andre-Guy Martin⁴, Eric Vigneault⁴, Fabio Cury⁵, Luis Souhami⁵, W. James Morris², Charles Catton⁶, Himu Lukka⁷; ¹London Health Sciences Centre, London, ON; ²British Columbia Cancer Agency, Vancouver, BC; ³British Columbia Cancer Agency, Kelowna, BC; ⁴L'Hotel Dieu de Quebec, Quebec City, QC; ⁵Montreal General Hospital, Montreal, QC; ⁶Princess Margaret Cancer Centre, Toronto, ON; ⁷Juravinski Cancer Centre, Hamilton, ON

12:50-1:00 **CLOSING REMARKS** Ross Halperin, Fabio Cury

2:00 **Golf – Nine and Dine** Tee times start at 3:00pm.

Enjoy the Harvest Experience – spectacular Okanagan views, award winning service, attention to detail and golf that is second to none! At 7109 yards, The Harvest is a championship length golf course on 254 acres designed by renowned Canadian golf course architect, Graham Cooke. \$65.00 per person.

3:00 **Wine Tasting**

Tour includes hotel pick up and drop off in a comfortable air conditioned vehicle, winery tasting and venue fees, a friendly, knowledgeable driver, a snack along the way and complimentary bottled water. Full refund if the tour is cancelled. \$89 per person (\$93.45 including GST).

POSTER ABSTRACTS

-
- 97 MEASURING SKIN DOSE IN BREAST BRACHYTHERAPY: DOES IT MATTER WHAT METRIC WE USE?** Michelle Hilts¹, Heather Halperin¹, Daniel Morton², Deidre Batchelar¹, Francois Bachand¹, Rezwan Chowdhury¹, Juanita Crook¹; ¹British Columbia Cancer Agency, Southern Interior, Kelowna, BC; ²University of Victoria, Victoria, BC
-
- 98 PLANNING CT SCANS FOR THE TREATMENT OF HDR VAGINAL VAULT BRACHYTHERAPY: AN EVALUATION OF ITS ROLE TO DETERMINE THE DOSE TO THE ORGANS AT RISK** Tracey Rose, Deidre Batchelar, Bart Robertson, Juanita Crook, David Petrik, Francois Bachand; University of British Columbia, Kelowna, BC
-
- 99 LONG TERM OUTCOMES AND LATE EFFECTS IN SURVIVORS OF CARCINOMA OF THE CERVIX TREATED WITH BRACHYTHERAPY** Gaurav Bahl¹, Evan Woo¹, Beverly Lester¹, Frances Wong²; ¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Surrey, BC
-
- 100 OUTCOMES FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER WITH CONCURRENT CHEMO-RADIATION + 2D HDR BRACHYTHERAPY (5 FRACTIONS OF 5.5GY)** Laura D'Alimonte¹, Ahmad Bushehri², Xingshan Cao³, Ida Ackerman², Lisa Barbera², Elizabeth A Barnes², Ananth Ravi², Eric Leung², Gillian Thomas²; ¹University of Toronto, Toronto, ON; ²Odette Cancer Centre, Toronto, ON; ³Sunnybrook Health Sciences Centre, Toronto, ON
-
- 101 LDR PROSTATE BRACHYTHERAPY REIMPLANT PROCEDURE FOLLOWING SUBOPTIMAL DOSIMETRY: LONG-TERM BIOCHEMICAL CONTROL RATES AND URINARY TOXICITY** Michael Peacock, Mira Keyes, Pickles Tom, Michael McKenzie, Vincent Lapointe, Ingrid Spadinger, W James Morris; University of British Columbia, Vancouver, BC
-
- 102 IMPROVING CERVICAL VOLUMETRIC DOSIMETRY WITH COMBINED INTRACAVITARY/ INTERSTITIAL BRACHYTHERAPY** Natalie Logie, Fleur Huang, Robert Pearcey, Ericka Wiebe, Jim Rose, Ron S. Sloboda, Geetha Menon; Cross Cancer Institute, Edmonton, AB
-
- 103 HIGH DOSE RATE BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: IS THERE AN OPTIMAL IMPLANT?** Joelle Helou¹, Gerard Morton², Melanie Davidson¹, Hans Chung¹, Andrew Loblaw¹, Laura D'Alimonte², Ananth Ravi²; ¹University of Toronto, Toronto, ON; ²Odette Cancer Centre, Toronto, ON
-
- 104 DOSIMETRIC AND VOLUMETRIC IMPACT OF ANATOMICAL CHANGES AND CATHETER DISPLACEMENT ON MULTI-FRACTION INTERSTITIAL GYNECOLOGICAL BRACHYTHERAPY TREATMENT PLAN QUALITY** Eric Leung¹, Matt Wronski¹, Melanie Davidson¹, Laura D'Alimonte¹, David D'Souza², Ananth Ravi¹; ¹Odette Cancer Centre, Toronto, ON; ²London Regional Cancer Program, London, ON
-
- 105 PERI-OPERATIVE MORBIDITY ASSOCIATED WITH THE USE OF BRACHYTHERAPY FOR CERVIX CANCER** Gaurav Bahl¹, Evan Woo¹, Beverly Lester¹, ²Frances Wong; ¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Surrey, BC
-
- 106 PHOTODYNAMIC THERAPY (PDT) WITH PORFIMER SODIUM SENSITIZER USING HDR PRINCIPLES FOR PLANNING: A SINGLE INSTITUTION EXPERIENCE OF AN ALTERNATIVE TREATMENT FOR LOCAL CANCER CONTROL** Mira Goldberg¹, Joseph Hayward¹, Richard Singh², Ranjan Sur¹; ¹Juravinski Cancer Centre, Hamilton, ON; ²Walker Family Cancer Centre, St. Catharines, ON
-
- 107 UNEXPECTED SEED MIGRATION IN PROSTATE BRACHYTHERAPY IMPLANTS COINCIDENT WITH CHANGE IN SEED STRANDING PRODUCT** Jim Rose, Derek Liu, Alex Boychuk, Ron Sloboda, Nadeem Pervez, Al Murtha, Don Yee, John Amanie, Nawaid Usmani; Cross Cancer Centre, Edmonton, AB
-
- 108 A PILOT STUDY AND EARLY EXPERIENCE WITH PERMANENT BREAST SEED IMPLANT (PBSI) USING PALLADIUM 103 SEEDS FOR PARTIAL BREAST RADIATION** Siraj Husain¹, Ivo Olivotto², Theresa Trotter², Michael Sia¹, Karen Long¹, Tyler Meyer¹; ¹Tom Baker Cancer Centre, Calgary, AB; ²University of Calgary, Calgary, AB
-
- 109 THE ROLE OF DEFORMABLE IMAGE REGISTRATION LOOKING AT SMALL BOWEL AND SIGMOID DURING MULTI-FRACTION ADAPTIVE IMAGE-GUIDED HDR BRACHYTHERAPY FOR CERVIX CANCER** Francois Bachand¹, Drew Phillips², Juanita Crook¹, David Petrik¹, Deidre Batchelar¹; ¹British Columbia Cancer Agency, Centre for Southern Interior, Kelowna, BC; ²University of British Columbia, Okanagan, Kelowna, BC
-
- 110 IMPLEMENTATION OF AN ULTRASOUND-BASED, SINGLE FRACTION PROSTATE HDR PROGRAM – ONE-YEAR REVIEW OF THE HALIFAX EXPERIENCE** Amanda Cherpak, Krista Chytky-Praznik, David Bowes, Nikhilesh Patil, Mammo Yewondwossen; Dalhousie University, Halifax, NS
-
- 111 DEFORMABLE IMAGE REGISTRATION FOR DOSE ACCUMULATION TO BLADDER AND RECTUM IN MULTI-FRACTION HIGH DOSE RATE BRACHYTHERAPY FOR CERVICAL CANCER** Deidre Batchelar¹, Drew Phillips², Juanita Crook¹, David Petrik¹, Francois Bachand¹; ¹British Columbia Cancer Agency, Kelowna, BC; ²University of British Columbia, Okanagan, Kelowna, BC
-
- 112 COMPARISON OF PLANNED AND IMPLANTED SEED POSITIONS IN PERMANENT BREAST SEED IMPLANT BRACHYTHERAPY** Daniel Morton¹, Michelle Hilts², Deidre Batchelar², Juanita Crook²; ¹University of Victoria, Kelowna, BC; ²British Columbia Cancer Agency, Centre for Southern Interior, Kelowna, BC
-

- 113 3D TRANS-RECTAL ULTRASOUND FOR HIGH-DOSE-RATE PROSTATE BRACHYTHERAPY: A COMPARISON OF 3D IMAGE VOLUMES WITH INTRA-OPERATIVE 2D IMAGING** Thomas Hrinivich¹, Douglas Hoover¹, Kathleen Surry¹, David D'Souza¹, Aaron Fenster², Eugene Wong¹; ¹Western University, London, ON; ²Robarts Research Institute, London, ON
- 114 VAGINAL VAULT BRACHYTHERAPY TREATMENT CANCELLATION FOR ENDOMETRIAL CANCER** Elizabeth Barnes, Lisa Barbera, Eric Leung, Gillian Thomas, Ida Ackerman; Odette Cancer Centre, Toronto, ON
- 115 PROSPECTIVE EVALUATION OF NORMAL TISSUE TOXICITY ASSOCIATED WITH BREAST BOOST IN EARLY-STAGE BREAST CANCER RADIOTHERAPY** Grace Lee, Nafisha Lalani, Nora Emad, Bethany Gill, Tony Panzarella, Anne Koch; Princess Margaret Cancer Centre, Toronto, ON
- 116 COSMETIC OUTCOME ASSESSMENT AFTER NEOADJUVANT RADIOCHEMOTHERAPY IN BREAST CANCER PATIENTS** Christiane Matuschek¹, Edwin Boelke¹, Vanessa Speer¹, Sylvia Wollandt², Werner Audretsch³, Arne Gerber¹, Wilfried Budach¹, Carolin Nestle Krämling²; ¹Heinrich Heine University, Dusseldorf, Germany; ²Gerresheim Hospital, Dusseldorf, Germany; ³Marien Hospital, Dusseldorf, Germany
- 117 TREATMENT APPROACHES, OUTCOMES, AND COMPLICATIONS IN INTRACRANIAL GERMINOMAS: THE BRITISH COLUMBIA CANCER AGENCY EXPERIENCE** Andrea Lo, Kelsi Taguchi, Alan Nichol, Haroon Hasan, Fuchsia Howard, Karen Goddard; University of British Columbia, Vancouver, BC
- 118 FACTORS AFFECTING POST-OPERATIVE SURGICAL CAVITY VOLUME AND SURFACE AREA DYNAMICS SPECIFIC TO BRAIN METASTASES** Yaser Hasan, Luluel Khan, Todd Mainprize, Sunit Das, Mark Ruschin, Fiona Lochray, Young Lee, May Tsao, Arjun Sahgal, Hany Soliman; University of Toronto, Toronto, ON
- 119 CLINICAL REVIEW AND TREATMENT OUTCOME IN GLIOBLASTOMA MULTIFORME: SASKATCHEWAN EXPERIENCE** Rashmi Koul¹, Gopinath Narasimhan², Arbind Dubey¹, Patricia Tie², Vamsee Torri², Anikidu S Kakumanu²; ¹CancerCare Manitoba, Winnipeg, MB; ²Saskatchewan Cancer Agency, Saskatoon, SK
- 120 COMPARING SINGLE ARC-VOLUMETRIC MODULATED ARC THERAPY (SA-VMAT) TO INTENSITY MODULATED RADIATION THERAPY (IMRT) FOR THE TREATMENT OF LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC)** Mira Goldberg¹, Jack Skoczny², Jasmin Vansantvoort², Orest Ostapiak², Marcin Wierzbicki², Greg Pond², Anand Swaminath², Gordon Okawara², Jim Wright², Theodoros Tsakiridis²; ¹McMaster University, ON; ²Juravinski Cancer Centre, Hamilton, ON
- 121 HYPOFRACTIONATED RADIATION OF PERIPHERAL, EARLY STAGE LUNG CARCINOMAS: DOSIMETRIC COMPARISONS OF 3D CONFORMAL, HYBRID ARC, AND VOLUMETRIC MODULATED ARC THERAPY** Susan Tyler, Chris Thomas, Krista Chytky-Praznik, Derek Wilke, Helmut Hollenhorst; Dalhousie University, Halifax, NS
- 122 SPATIALLY FRACTIONATED RADIOTHERAPY USING A MEDICAL LINEAR ACCELERATOR MOUNTED MINI-BEAM COLLIMATOR** Gavin Cranmer-Sargison¹, Cody Crewson¹, William Davis², Andrew Alexander¹, Vijayananda Kundapur¹; ¹Saskatchewan Cancer Agency, Saskatoon, SK; ²University of Saskatchewan, Saskatoon, SK
- 123 A MIXED METHODS SURVEY ON THE IMPACT OF A DIFFICULT CANADIAN JOB MARKET ON RADIATION ONCOLOGY RESIDENTS AND PROGRAM DIRECTORS** Joshua Giambattista¹, Shilo Lefresne¹, Rob Olson², Hannah Carolan¹, Shaun Loewen³; ¹University of British Columbia, Vancouver, BC; ²University of British Columbia, Prince George, BC; ³University of Manitoba, Winnipeg, MB
- 124 WHY ARE YOUNG WOMEN GETTING LOCALLY ADVANCED CERVIX CANCER DESPITE SCREENING?** David D'Souza¹, Nikhilesh Patil², Eric Leung³, Elizabeth Jewlal¹, Heather Shaddick¹, Akira Sugimoto¹, Jacob McGee¹, Michel Prefontaine¹; ¹Western University, London, ON; ²Dalhousie University, Halifax, NS; ³University of Toronto, Toronto, ON
- 125 STOP! IN THE NAME OF SAFETY: THE SINGLE FRACTION CHECKLIST – AN ASSESSMENT TOOL FOR HIGH RISK TREATMENT SCENARIOS** Brian Liszewski¹, Lisa Di Prospero², Krista Dawdy², Paulette McKeon², Kari Osmar², Stephen Russell²; ¹Odette Cancer Centre, Toronto, ON; ²University of Toronto, Toronto, ON
- 126 #RADONC: FEASIBILITY OF THE GLOBAL TWITTER-BASED RADIATION ONCOLOGY JOURNAL CLUB FOR COLLABORATIVE EDUCATION ON RESEARCH AND PRACTICE** Ian Pereira¹, Miriam Knoll², Brandon Mancini³, Matthew Katz⁴, Zain Husain³; ¹Queen's University, Kingston, ON; ²Mt. Sinai Medical Center in New York, New York, NY, USA; ³Yale-New Haven Hospital, New Haven, CT, USA; ⁴Lowell General Hospital, Lowell, MA, USA
- 127 UNRAVELLING A COMPLEX WEB: THE QUALITY OF ONLINE RESOURCES FOR CANCER PATIENTS** Paris-Ann Ingledew¹, Elena Scali², Diala El-Zammar², Irene Yu², Baljeet Brar², Julia Lin², Eva Gusnowski²; ¹British Columbia Cancer Agency, Fraser Valley, Surrey, BC; ²University of British Columbia, Vancouver, BC
- 128 MINI-CEX ASSESSMENTS FOR RADIATION ONCOLOGY RESIDENTS: PILOT IMPLEMENTATION AND EVALUATION** Joanne Alfieri, Khalil Sultanem; McGill University, Montreal, QC
- 129 THINKING INSIDE THE BOX: A STANDARDIZED RADIATION THERAPY CONSOLE LAYOUT** Brian Liszewski; Odette Cancer Centre, Toronto, ON
- 130 CONCURRENT THERAPY TREATMENT SCHEDULING: INTERDEPARTMENTAL START DATE COORDINATION** Brian Liszewski¹, Jonte Boysen², Justin Mangera², Ghazi Merie², Anis Rabie², Jackie Ezezika²; ¹Odette Cancer Centre, Toronto, ON; ²University of Toronto, Toronto, ON

- 131 THE RADIATION LEGACY PROJECT: DEVELOPING AN INTERPROFESSIONAL RESOURCE FOR PALLIATIVE RADIOTHERAPY** Christine Hill¹, Angela Cashell², Fred Cheung², Andrea Bezjak², Bernard Cummings², Wilfred Levin², Rebecca Wong², Michelle Lau¹, Christine Zywine², Jolie Ringash²; ¹University Health Network, Toronto, ON; ²University of Toronto, Toronto, ON
- 132 PLERIXAFOR INHIBITS MYELOID CELL RECRUITMENT AND IMPROVES THE RADIOCURABILITY OF CERVICAL CANCER** Naz Chaudary, Melania Pintilie, Richard P. Hill, Michael Milosevic; University of Toronto, Toronto, ON
- 133 DOES VMAT/IMRT FOR ANAL CANAL CANCER INCREASE THE RISK OF NEUTROPENIA AND/OR RADIATION TREATMENT BREAKS?** Darindra Gopaul¹, Ryan Urban², Justin Ling³, Andrew Costa²; ¹Grand River Hospital, Kitchener, ON; ²McMaster University, Kitchener, ON; ³University of Waterloo, Waterloo, ON
- 134 18F-FLUOROCHOLINE (18F-FCH) HYBRID PET/MRI IN THE EVALUATION OF MEN WITH SUSPECTED PROSTATE CANCER RECURRENCE FOLLOWING DEFINITIVE LOCAL THERAPY: A PROSPECTIVE STUDY** Tina W. Zhang¹, Zahra Kassam², Irina Rachinsky¹, Cesare Romagnoli¹, David D'Souza¹, Varagur Venkatesan¹, Belal Ahmad¹, Joseph Chin¹, Stephen Pautler¹, John Butler¹, Jonathan Thiessen¹, Ashley Lozanski¹, Peter Chung², Cynthia Menard², Ty Lee¹, Glenn Bauman¹; ¹Western University, London, ON; ²University of Toronto, Toronto, ON
- 135 ARE RESULTS FROM INTERMEDIATE RISK PROSTATE CANCER PATIENTS TREATED WITHIN CLINICAL TRIALS APPLICABLE TO REAL LIFE PATIENTS?** Xavier Liem, Jean-Paul Bahary, Guila Delouya, Marie-Claude Beauchemin, Carole Lambert, Marie Barkati, Daniel Taussky; Université de Montréal, Montréal, QC
- 136 PROSTATE APEX CONTOURING** Eduardo Gavioli, Ian Dayes, Angela Lin, Gregory Pond, Thomas Chow; McMaster University, Hamilton, ON
- 137 DEVELOPMENT OF AN EDUCATION RESOURCE FOR POST-PROSTATECTOMY PROSTATE CANCER PATIENTS WHO REQUIRE RADIOTHERAPY** Ewa Szumacher¹, Merrylee McGuffin¹, Aaron Cumal¹, Eirena Calabreses¹, Deb Feldman-Stewart², Julie Burnett¹, Janet Ellis¹, Eli Lechtman¹, Lisa DiProspero¹, Christopher Townsend¹, Tamara Harth¹; ¹University of Toronto, Toronto, ON; ²Queen's University, Kingston, ON
- 138 PATHOLOGY AND OUTCOME OF NON-SQUAMOUS CELL PENILE CANCER OVER TEN-YEAR PERIOD** Melody Xuan Lu Qu, Aamer Mahmud; Queen's University, Kingston, ON
- 139 RETROSPECTIVE REVIEW OF OUTCOMES WITH ACTIVE SURVEILLANCE AND ACTIVE TREATMENT FOR EARLY STAGE PROSTATE CANCER IN A CONTEMPORARY SERIES AT DR.H.B.MURPHY CANCER CENTRE** Jinka Sathya¹, Catherine Nicholson¹, John Thoms², Asim Kamran², Veeresh Gadag¹; ¹Memorial University of Newfoundland, St. John's, NL; ²Dr.H.Bliss Murphy Cancer Centre, St. John's, NL
- 140 ACTIVE SURVEILLANCE IN INTERMEDIATE RISK PATIENTS: OVERALL AND CAUSE-SPECIFIC SURVIVAL IN THE SUNNYBROOK EXPERIENCE** Hima Bindu Musunuru¹, Laurence Klotz¹, Danny Vesprini¹, Liying Zhang¹, Perakaa Sethukavalan¹, Alexandre Mamedov¹, Vibhuti Jethava¹, Suneil Jain², Toshihiro Yamamoto¹, Andrew Loblaw¹; ¹University of Toronto, Toronto, ON; ²Queen's University, Belfast, Ireland
- 141 TESTOSTERONE FLARE IN PATIENTS WITH HIGH RISK LOCALIZED PROSTATE CANCER RECEIVING LUTEINIZING HORMONE RELEASING HORMONE AGONISTS IN A PROSPECTIVE NON-RANDOMIZED CLINICAL TRIAL** Andrew Loblaw, Evelyn Elias, Patrick Cheung, William Chu, Hans Chung, Gerard Morton, Danny Vesprini, Ewa Szumacher, Stanley Liu, Perakaa Sethukavalan, Vibhuti Jethava; Odette Cancer Centre, Toronto, ON
- 143 PILOTING PROSTATE CANCER PATIENT-REPORTED OUTCOMES IN CLINICAL PRACTICE** Martin Korzeniowski¹, Maria Kalyvas¹, Aamer Mahmud¹, Carey Shenfield¹, Christine Tong¹, Khaled Zaza¹, Doris Howell², Michael Brundage¹; ¹Queen's University, Kingston, ON, Canada; ²University of Toronto, Toronto, ON
- 144 STEREOTACTIC BODY RADIATION THERAPY FOR UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA** Fabio Cury¹, Sero Andonian¹, Alan Dal Pra², Houda Bahig³, William Parker¹; ¹McGill University Health Centre, Montreal, QC; ²Bern University Hospital, Bern, Switzerland; ³Centre Hospitalier de l'Université de Montréal, Montreal, QC
- 145 HEALTHY BONES STUDY: IMPROVING HEALTHY BONE BEHAVIOURS IN PROSTATE CANCER PATIENTS ON ANDROGEN DEPRIVATION THERAPY** Derek Tsang, Osai Samadi, William Jeon, Joshua To, Henriette Breunis, Jennifer Jones, Charles Catton, Shabbir Alibhai; University of Toronto, Toronto, ON
- 146 DIFFICULT DIAGNOSIS OF METASTATIC GERM CELL TUMOUR** Kate Johnson¹, Bryan Brunet²; ¹University of Manitoba, Winnipeg, MB; ²University of Saskatchewan, Saskatoon, SK
- 147 SUNNYBROOK FAMILIAL PROSTATE CANCER CLINIC (FPCC) AND MALE ONCOLOGY AND RESEARCH (MORE) PROGRAM** Justin Lorentz, Gabriella Ghanem, Danny Vesprini; Odette Cancer Centre, Toronto, ON
- 148 AN EXPLORATORY MODEL TO PREDICT THE LIKELIHOOD OF RADIATION TOXICITY OF A PROSTATE CANCER PATIENT AFTER TREATMENT INCORPORATING GENOMIC, CLINICAL AND DOSIMETRIC VARIABLES** Sandeep Singhal¹, Nawaid Usmani¹, David Broadhurst¹, Sarah Kerns², Barry Rosenstein³, Michael Sia⁴, Matthew Parliament¹; ¹University of Alberta, Edmonton, AB; ²University of Rochester, Rochester, NY, USA; ³Mount Sinai School of Medicine, New York, NY, USA; ⁴Tom Baker Cancer Centre, Calgary, AB

- 149 DOES ERG PROTEIN EXPRESSION PREDICT FOR RELAPSE AFTER A PROSTATE BRACHYTHERAPY IMPLANT?** Nawaid Usmani¹, Khalifa Al-Kaabi¹, Sunita Ghosh¹, Jesse Hill¹, Cian Hackett¹, Moore Harrison¹, A Box², S Hegazy², John Pedersen¹, Albert Murtha¹, Nadeem Pervez¹, John Amanie¹, Don Yee¹, Tarek Bismar²; ¹University of Alberta, Edmonton, AB; ²University of Calgary, Calgary, AB
- 150 METFORMIN USE IS ASSOCIATED WITH LOWER CERVICAL CANCER-SPECIFIC MORTALITY** Kathy Han¹, Melania Pintilie¹, Lorraine L Lipscombe², Ilana Lega², Michael Milosevic¹, Anthony Fyles¹; ¹Princess Margaret Cancer Centre, Toronto, ON; ²Women's College Hospital, Toronto, ON
- 151 A COMPARISON OF 3DCRT, IMRT, AND VMAT PELVIC RADIATION FOR QUALITATIVE AND QUANTITATIVE TOXICITY** Sheri Lomas¹, Christina Parsons¹, Francois Bachand², Peter Lim¹; ¹British Columbia Cancer Agency, Vancouver, BC; ²British Columbia Cancer Agency, Kelowna, BC
- 152 OUTCOMES IN T1 GLOTTIC CANCER TREATED WITH RADIOTHERAPY: A SINGLE INSTITUTION EXPERIENCE** Tina W. Zhang¹, Tsu-Hui (Hubert) Low¹, David Yeh¹, Rakhna Araslanova¹, J. Alex Hammond¹, David A. Palma¹, Nancy Read¹, Kevin Fung¹, Danielle MacNeil¹, Anthony C. Nichols¹, John Yoo², Varagur Venkatesan¹; ¹Western University, London, ON; ²London Health Sciences Centre, London, ON
- 153 CONCURRENT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECK CANCER: IMPACT OF RADIATION TECHNIQUE, CISPLATIN DOSE, AND TUMOUR HPV STATUS** Shao Hui Huang, Spreffico Anne, Wei Xu, Chen Liu, John Waldron, Eric Chen, Jolie Ringash, Andrew Bayley, Kelvin Chan, Andrew Hope, Albiruni Razak, Bayardo Perez-Ordóñez, Ilan Weinreb, John Cho, Raymond Jang, Aaron Hansen, Yuyao Song, Brian O'Sullivan, Lillian Siu, John Kim; University of Toronto, Toronto, ON
- 154 OUTCOMES OF STAGE II GLOTTIC CANCER IN A SINGLE INSTITUTION: CONVENTIONAL VERSUS INTENSITY MODULATED RADIOTHERAPY** Tina W. Zhang¹, Tsu-Hui (Hubert) Low¹, David Yeh¹, Rakhna Araslanova¹, J. Alex Hammond¹, David A. Palma¹, Nancy Read¹, Kevin Fung¹, Danielle MacNeil¹, Anthony C. Nichols¹, John Yoo², Varagur Venkatesan¹; ¹Western University, London, ON; ²London Health Sciences Centre, London, ON
- 155 NATURAL COURSE FOLLOWING FAILURE AFTER DEFINITIVE (CHEMO-) RADIOTHERAPY IN HPV-RELATED AND HPV-UNRELATED OROPHARYNGEAL CANCER** Shrinivas Rathod, Shao Hui Huang, John Kim, Susie Su, Wei Wu, John Waldron, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, Jolie Ringash, Aaron Hansen, David Goldstein, Li Tong, Bayardo Perez-Ordóñez, Ilan Weinreb, Brian O'Sullivan; Princess Margaret Cancer Centre, Toronto, ON
- 156 OUTCOME FOLLOWING DEFINITIVE RADIOTHERAPY FOR SQUAMOUS CELL CARCINOMA OF THE NASAL VESTIBULE** Ibrahim Atean, Shao Hui Huang, John Waldron, Yuyao Song, Wei Xu, Andrew Bayley, Scott Bratman, Meredith Giuliani, Andrew Hope, John Kim, Jolie Ringash, Jonathan Irish, Brian O'Sullivan; Princess Margaret Cancer Centre, Toronto, ON
- 157 RANDOMIZED STUDY OF NUTRITIONAL STATUS AND TREATMENT TOXICITIES OF ORAL IMMUNONUTRITION DURING CONCURRENT CHEMORADIOTHERAPY FOR HEAD AND NECK CANCER PATIENTS** Imjai Chitapanarux¹, Ekasit Tharavichitkul¹, Somvilai Jakrabhandu¹, Pitchayaponne Klunklin¹, Wimrak Onchan¹, Bongkot Supawongwattana¹, Patrinee Traisathit¹, Veeradej Pisprasert²; ¹Chiang Mai University, Chiang Mai, Thailand; ²Khon Kaen University, Khon Kaen, Thailand
- 158 IMPACT OF SURGICAL MARGINS ON OUTCOMES IN ORAL CAVITY SQUAMOUS CELL CARCINOMA MANAGED WITH SURGERY AND POSTOPERATIVE RADIOTHERAPY** Ali Hosni, Shao Hui Huang, Wei Xu, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, John Kim, Jolie Ringash, John Waldron, David Goldstein, Eric Chen, Brian O'Sullivan, Andrew Hope; University of Toronto, Toronto, ON
- 159 MAJOR SALIVARY GLAND CARCINOMA: INDEPENDENT PROGNOSTIC FACTORS FOR DISTANT METASTASIS AND SURVIVAL** Ali Hosni, Shao Hui Huang, David Goldstein, Wei Xu, Biu Chan, Aaron Hansen, Andrew Bayley, Scott Bratman, John Cho, Meredith Giuliani, Andrew Hope, John Kim, Brian O'Sullivan, John Waldron, Jolie Ringash; University of Toronto, Toronto, ON
- 160 EVALUATING THE IMPACT OF A CLINICAL SPECIALIST RADIATION THERAPIST (CSRT) ON COMPLEX RADIATION TREATMENT PLANNING** Sylvia Mitchell¹, David Palma², Alex Hammond¹, Nancy Read¹, Varagur Venkatesan¹; ¹London Health Sciences Centre, London, ON; ²London Regional Cancer Program, London, ON
- 161 OPTIMAL DETECTION OF HYPOTHYROIDISM IN EARLY STAGE LARYNGEAL CANCER TREATED WITH RADIOTHERAPY** Han Zhang¹, Graeme Mulholland¹, Hadi Seikaly¹, Nicholas Tkaczuk², Nhu-Tram Nguyen³, Daniel A. O'Connell¹, Vincent L. Biron¹, Jeffrey R. Harris¹; ¹University of Alberta, Edmonton, AB; ²Northern Ontario School of Medicine, Thunder Bay, ON; ³McMaster University, Hamilton, ON
- 162 QUALITY OF LIFE (QOL) FOLLOWING SEQUENTIAL BOOST REGIMEN (SB) WITH HELICAL TOMOTHERAPY INTENSITY MODULATED RADIOTHERAPY (HTIMRT) IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK CANCER (SCCHN)** Mohammed Y Almaghrabi, Horia Marginean, Samy El-Sayed; University of Ottawa, Ottawa, ON

- 163** **PROPHYLACTIC VERSUS REACTIVE INTRAVENOUS HYDRATION IN PATIENTS WITH SQUAMOUS CELL CANCER OF THE HEAD AND NECK TREATED WITH CISPLATIN-BASED CHEMORADIATION** Beverly Lester, Melanie Chevrier, Harlyn Hunter, Dorothy Uhlman, Fred Hsu; *University of British Columbia, Abbotsford, BC*
- 164** **A METHODOLOGY TO ASSESS DOSIMETRIC CHANGES IN THE TARGET VOLUMES AND ORGANS AT RISK DURING RADIOTHERAPY FOR HEAD AND NECK CANCER PATIENTS USING WEEKLY KV CBCT AND DEFORMABLE REGISTRATION** Luminita Nica¹, Tony Popescu¹, Roja Zakariaee², Moira Pearson¹, Tania Arora¹, Jenny Soo¹, Alison Giddings¹, Eric Berthelet²; *¹British Columbia Cancer Agency, Vancouver, BC; ²University of British Columbia, Vancouver, BC*
- 165** **CLINICAL OUTCOMES FOLLOWING RE-IRRADIATION IN HEAD AND NECK CANCERS** Satiavani Ramasamy, Shao Hui Huang, Susie Su, Wei Xu, John Waldron, John Cho, Andrew Hope, Andrew Bayley, John Kim, Jolie Ringash, Scott Bratman, Raymond Jang, David Goldstein, Brian O'Sullivan, Meredith Giuliani; *University of Toronto, Toronto, ON*
- 166** **TREATMENT OUTCOMES OF LOCO-REGIONALLY ADVANCED OROPHARYNGEAL CANCER: POTENTIAL EFFECT OF REDUCED CONCURRENT SYSTEMIC THERAPY AND THE CONFOUNDING EFFECT OF SMOKING HISTORY** Hosam Kader, Sally Smith, Cheryl Alexander, Stacey Gossman; *British Columbia Cancer Agency, Vancouver Island Centre, Victoria, BC*
- 167** **EGFR MUTATION STATUS ON THE METASTATIC BEHAVIOR OF NON-SMALL CELL LUNG CANCER** David Anderson¹, Alex De Caluwe¹, Ted Toriumi¹, Cheryl Ho², Fred Hsu¹; *¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Vancouver, BC*
- 168** **OVERALL SURVIVAL FOR STAGE I NON-SMALL CELL LUNG CANCER TREATED WITH RADIOTHERAPY ALONE; A SINGLE INSTITUTION RETROSPECTIVE STUDY** Oliver Holmes, Graham Cook, Robert MacRae, Peter Cross, Jason R Pantarotto; *University of Ottawa, Ottawa, ON*
- 169** **IS THERE A ROLE FOR PROPHYLACTIC CRANIAL IRRADIATION IN PATIENTS WITH EXTRA-PULMONARY SMALL CELL CARCINOMA?** Gail Bowering¹, Alex DeCaluwe¹, Alan Nichol², Fred Hsu¹; *¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Vancouver, BC*
- 170** **MEDIAN OVERALL SURVIVAL IN ELDERLY PATIENTS AFTER STEREOTACTIC BODY RADIOTHERAPY (SABR) FOR EARLY LUNG CANCERS – DOES AGE MATTER?** Devin Schellenberg¹, Maryam Dosani², Ruobing Yang², Annie Houle², Jonn Wu², Steven Thomas¹, Hannah Carolan², Mitchell Liu², Rezwan Chowdhury³, Chad Lund¹; *¹British Columbia Cancer Agency, Surrey, BC; ²British Columbia Cancer Agency, Vancouver, BC; ³British Columbia Cancer Agency, Kelowna, BC*
- 171** **CLINICAL OUTCOMES OF A PATIENT-ADAPTED TREATMENT TECHNIQUE SELECTION ALGORITHM IN LUNG SABR** Houda Bahig, Edith Filion, Toni Vu, Louise Lambert, Dominique Mathieu, David Roberge, Julie Prenovault, Caroline Lavoie, Myriam Bouchard, Robert Doucet, Marie-Pierre Campeau; *Centre Hospitalier de l'Université de Montréal, Montreal, QC*
- 172** **STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR PULMONARY OLIGOMETASTASES AND OLIGOPROGRESSION** Joelle Helou, Isabelle Thibault, Latifa Yeung, Ian Poon, Michael Tjong, Andrew Chiang, Suneil Jain, Hany Soliman, Patrick Cheung; *University of Toronto, Toronto, ON*
- 173** **WHEN IS WITHHOLDING STEREOTACTIC ABLATIVE RADIOTHERAPY JUSTIFIED? PREDICTING EARLY MORTALITY IN EARLY-STAGE LUNG CANCER PATIENTS** Alex Louie¹, Cornelis Haasbeek², George Rodrigues¹, Frank Lagerwaard², David Palma¹, Andrew Warner¹, Ben Slotman², Suresh Senan²; *¹London Regional Cancer Program, London, ON; ²VU University, Amsterdam, Netherlands*
- 174** **EGFR MUTATION TESTING IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER – EARLY PATTERN OF PRACTICE IN BRITISH COLUMBIA** David Anderson¹, Fred Hsu¹, Alex DeCaluwe¹, Ted Toriumi¹, Yvonne Zheng², Cheryl Ho²; *¹British Columbia Cancer Agency, Abbotsford, BC; ²British Columbia Cancer Agency, Vancouver, BC*
- 175** **INCIDENCE OF BRAIN METASTASIS AND OUTCOMES IN PULMONARY LARGE CELL NEUROENDOCRINE CARCINOMA** Yizhou Zhao¹, David Bowes¹, Mathieu Castonguay¹, Zhaolin Xu¹, Madelaine Plourde¹, Liam Mulroy¹, Mary MacNeil¹, Ron Dewar²; *¹Dalhousie University, Halifax, NS; ²Cancer Care Nova Scotia, Halifax, NS*
- 176** **PROGNOSTIC VALUE OF PRETREATMENT NEUTROPHIL-LYMPHOCYTE RATIO ON OUTCOMES IN LUNG SBRT** Meredith Giuliani, Olive Wong, Jenna Gay, Lisa Le, B.C. John Cho, Alexander Sun, Andrea Bezjak, Anthony Brade, Andrew Hope; *Princess Margaret Cancer Centre, Toronto, ON*
- 177** **LOCATION, LOCATION, LOCATION. DOES A LOCAL LUNG STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) PROGRAM INCREASE UTILIZATION?** Devin Schellenberg¹, Elaine Wai², Tanya Berrang², Islam Mohamed³, Rezwan Chowdhury³, Ivo Olivetto⁴, Ross Halperin⁵; *¹British Columbia Cancer Agency, Surrey, BC; ²British Columbia Cancer Agency, Victoria, BC; ³British Columbia Cancer Agency, Kelowna, BC; ⁴University of Calgary, Calgary, AB; ⁵British Columbia Cancer Agency, Vancouver, BC*
- 178** **CAN CONCURRENT CHEMO-RADIATION BE DELAYED BY INDUCTION CHEMOTHERAPY IN THE CURATIVE TREATMENT OF STAGE III NON-SMALL CELL LUNG CARCINOMA?: A POOLED ANALYSIS** Aurelie Garant, Catherine Guilbault, Muneera Almajed, Sergio Faria, Scott Owen, Marie Duclos, Linda Ofiara, James Gruber, Vera Hirsh, Neil Kopeck; *McGill University, Montreal, QC*

- 179 PATTERNS OF FAILURE IN EGFR-MUTANT LUNG ADENOCARCINOMA FOLLOWING TYROSINE KINASE INHIBITOR THERAPY: CANDIDATES FOR STEREOTACTIC BODY RADIATION THERAPY** Hani Al-Halabi¹, Karl Sayegh², Subba Dugamurthy², Andrzej Niemierko², Lecia Sequist², Henning Willers²; ¹Montreal General Hospital, Montreal, QC; ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 180 THORACIC RADIOTHERAPY FOR EXTENSIVE STAGE SMALL CELL LUNG CANCER: A META-ANALYSIS** David Palma¹, Andrew Warner¹, Suresh Senan², Alex Louie¹, Ben Slotman², George Rodrigues¹; ¹Western University, London, ON; ²VU University Medical Center, Amsterdam, Netherlands
- 181 LIMITED-DISEASE SMALL CELL LUNG CANCER (LSCCL): DO WE REALLY NEED LONG TREATMENTS WITH HIGHER DOSES?** Guy-Anne Turgeon, Neil Kopek, Luis Souhami, Vera Hirsh, Linda Ofiara, Faria Sergio; McGill University Health Centre, Montreal, QC
- 182 HYPOFRACTIONATED RADIATION FOR NASAL-TYPE EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA (ENKTL) IS NOT INFERIOR TO STANDARD DOSE FRACTIONATION SCHEDULE** Amandeep Taggar, Theresa Trotter, Douglas Stewart, Alexander Balogh; University of Calgary, Calgary, AB
- 183 EVALUATION OF A NOVEL QUANTITATIVE DIGITAL PATHOLOGY (QDP) TECHNIQUE AS A TOOL FOR PREDICTING PROSTATE CANCER RECURRENCE** Andrea Lo¹, Calum MacAulay¹, Mira Keyes¹, Robert Bristow², Colin Collins¹, Ladan Fazli¹, Martin Gleave¹, Martial Guillaud¹, Jagoda Korbelik¹, Malcolm Hayes¹, Branko Palcic¹; ¹University of British Columbia, Vancouver, BC; ²University of Toronto, Toronto, ON
- 184 THREE-DIMENSIONAL NUCLEAR PROFILES OF CIRCULATING TUMOUR CELLS IN HIGH-RISK PROSTATE CANCER PATIENTS UNDERGOING RADIOTHERAPY AND ANDROGEN DEPRIVATION** Landon Wark, Harvey Quon, Aldrich Ong, Shahida Ahmed, Rashmi Koul, Amit Chowdhury, Sabine Mai; University of Manitoba, Winnipeg, MB
- 185 CIRCULATING TUMOUR MICROPARTICLES AS A PROGNOSTIC INDICATOR OF LOCALLY ADVANCED COLORECTAL CANCER** Jacqueline Lam¹, Dae Kim², Colleen Biggs², Connor MacMillan², Siddika Pardhan², Hon Leong², Barbara Fisher²; ¹London Regional Cancer Program, London, ON; ²Western University, London, ON
- 186 MEASUREMENT OF TUMOUR HYPOXIA IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER USING POSITRON EMISSION TOMOGRAPHY (PET) WITH 18F-FLUOROAZOMYCIN ARABINOSIDE (18F-FAZA)** Kathy Han, Ur Metser, Ivan Yeung, Tina Shek, Jay Detsky, Wilfred Levin, Lee Manchul, Doug Vines, Anthony Fyles, Michael Milosevic; Princess Margaret Cancer Centre, Toronto, ON
- 187 RADIATION THERAPIST RESEARCH; A REVIEW OF PUBLISHED ABSTRACTS FROM CARO AND ESTRO MEETINGS FROM 2004 TO 2014** Kelly Linden¹, Kristopher Dennis²; ¹Ottawa Hospital, Ottawa, ON; ²University of Ottawa, Ottawa, ON
- 188 METASTATIC BEHAVIOR OF EXTRA-PULMONARY SMALL CELL CARCINOMA** Gail Bowering, Alex DeCaluwe, Fred Hsu; British Columbia Cancer Agency, Abbotsford, BC
- 189 RECOMMENDATIONS FOR THE REFERRAL OF PATIENTS FOR PROTON THERAPY** Samir Patel¹, Xanthoula Kostaras², Mathew Parliament¹, Ivo A Olivetto³, Robert Nordal³, Keith Aronyk¹, Neil Hagen²; ¹University of Alberta, Edmonton, AB; ²Alberta Health Services, Calgary, AB; ³University of Calgary, Calgary, AB
- 190 PHASE II STUDY: 0-7-21 HYPOFRACTIONATED PALLIATIVE RADIOTHERAPY FOR ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS** Nhu-Tram A. Nguyen, Lilian Doerwald-Munoz, Jim Wright, Do-Hoon Kim, Stephen Sagar, David Ian Hodson; McMaster University, Hamilton, ON
- 191 A PILOT STUDY TO EVALUATE URINARY CYTOKINES/CHEMOKINES AS MARKERS OF PAIN FLARE IN PATIENTS UNDERGOING EXTERNAL BEAM RADIOTHERAPY FOR THE TREATMENT OF PAINFUL BONE METASTASES** Ahmad Bushehri¹, Mark Pasetka², Kristopher Dennis³, Amanda Hird², Edward Chow¹, Carlo De Angelis¹; ¹University of Toronto, Toronto, ON; ²Odette Cancer Centre, Toronto, ON; ³University of Ottawa, Ottawa, ON
- 192 INCIDENCE AND TREATMENT PATTERS OF COMPLICATED BONE METASTASES IN A POPULATION-BASED RADIOTHERAPY PROGRAM** Manpreet Tiwana, Mark Barnes, Emily Yurkowski, Kelsey Roden, Robert Olson; British Columbia Cancer Agency, Centre for the North, Prince George, BC
- 193 MULTIDISCIPLINARY SURVIVAL PREDICTION FOR PATIENTS WITH ADVANCED CANCER** Kim Paulson, Brock Debenham, Bronwen LeGuerrier, Sunita Ghosh, Fleur Huang, Sharon Watanabe, Karen Chu, Ann Huot, John Amanie, Tirath Nijjar, Samir Patel, Jim Rose, Diane Severin, Ericka Wiebe, Brita Danielson, Alysa Fairchild; University of Alberta, Edmonton, AB
- 194 PREVALANCE OF PATIENT REPORTED DEPRESSION AT TIME OF RADIOTHERAPY PLANNING FOR BRAIN METASTASES: IMPACT ON RADIATION THERAPIST AND COUNSELING SERVICES** Robert Olson¹, Douglas Ozier², Vincent LaPointe², Allison Walter², Gale Bowering³, Susan Curtis⁴, Alan Nichol²; ¹British Columbia Cancer Agency, Centre for the North, Prince George, BC; ²British Columbia Cancer Agency, Vancouver Centre, Vancouver, BC; ³British Columbia Cancer Agency, Abbotsford Centre, Abbotsford, BC; ⁴British Columbia Cancer Agency, Fraser Valley Centre, Surrey, BC


- 195 A MULTICENTRE ANALYSIS OF WHOLE BRAIN REIRRADIATION FOR MULTIPLE BRAIN METASTASES: DOSE IS ASSOCIATED WITH SURVIVAL** Natalie Logie¹, Rachel Jimenez², Natalie Pulenzas³, Kelly Linden⁴, Denise Ciafone⁵, Sunita Ghosh¹, Shilo Lefresne⁶, Yuhui Xu⁴, Erin Wong³, Christina H. Son⁷, Helen A. Shih², William W. Wong⁵, Kristopher Dennis⁴, Edward Chow³, Alysa Fairchild¹; ¹Cross Cancer Institute, Edmonton, AB; ²Massachusetts General Hospital, Boston, MA, USA; ³Sunnybrook Health Sciences Centre, Toronto, ON; ⁴Ottawa Hospital Cancer Centre, Ottawa, ON; ⁵Mayo Clinic, Scottsdale, AZ, USA; ⁶British Columbia Cancer Agency, Vancouver, BC; ⁷University of Chicago, Chicago, IL, USA
- 196 FREQUENCY OF DISTAL BONE METASTASES IN PATIENTS TREATED FOR PALLIATIVE RADIOTHERAPY AND ASSOCIATIONS WITH PRIMARY TUMOUR TYPES** Mark Barnes¹, Manpreet Tiwana¹, Andrew Kiraly², Robert Olson³; ¹British Columbia Cancer Agency, Centre for the North, Prince George, BC; ²University of Northern BC, Prince George, BC; ³University of British Columbia, Prince George, BC
- 197 COMPARISON OF PATIENT-REPORTED OUTCOMES WITH SINGLE VERSUS MULTIPLE FRACTION PALLIATIVE RADIOTHERAPY FOR COMPLICATED BONE METASTASIS** Jessica Conway¹, Justin Glazier², Emily Yurkowski³, Quinn Gentles³, Robert Olson³; ¹British Columbia Cancer Agency, Vancouver, BC; ²Royal College of Surgeons in Ireland, Dublin, Ireland; ³University of British Columbia, Prince George, BC
- 198 CLINICAL SPECIALIST RADIATION THERAPIST IN PALLIATIVE RADIATION THERAPY; REPORT OF AN ORIENTATION AND TRAINING PROGRAM** Kelly Linden¹, Julie Renaud¹, Kristopher Dennis²; ¹The Ottawa Hospital, Ottawa, ON; ²University of Ottawa, Ottawa, ON
- 199 EFFECTS OF POLICY ON CODE STATUS DOCUMENTATION FOR ONCOLOGY IN-PATIENTS** Elyse Doiron¹, Camilla Zimmermann², Jennifer Woodland¹, Amanda Caissie¹; ¹Dalhousie University, Saint John, NB; ²Princess Margaret Cancer Centre, Toronto, ON
- 200 APPLICATION OF THE RECURSIVE PARTITIONING ANALYSIS SCORE AT CRANIAL REIRRADIATION FOR MULTIPLE BRAIN METASTASES** Natalie Logie¹, Rachel Jimenez², Natalie Pulenzas³, Kelly Linden⁴, Denise Ciafone⁵, Sunita Ghosh¹, Yuhui Xu⁴, Shilo Lefresne⁶, Erin Wong³, Christina H. Son⁷, Helen A. Shih², William W. Wong⁵, Kristopher Dennis⁴, Edward Chow³, Alysa Fairchild¹; ¹Cross Cancer Institute, Edmonton, AB; ²Massachusetts General Hospital, Boston, MA, USA; ³Sunnybrook Health Sciences Centre, Toronto, ON; ⁴The Ottawa Hospital Cancer Centre, Ottawa, ON; ⁵Mayo Clinic, Scottsdale, AZ, USA; ⁶British Columbia Cancer Agency, Vancouver, BC; ⁷University of Chicago, Chicago, IL, USA
- 201 NEEDS ASSESSMENT FOR PEDIATRIC PROTON THERAPY IN CANADA** Samir Patel¹, James A Whitlock², Ivo A Olivetto³, Matthew Parliament¹, Normand Laperriere², Eric Bouffet², D. D. Eisenstat¹; ¹University of Alberta, Edmonton, AB; ²University of Toronto, Toronto, ON; ³University of Calgary, Calgary, AB
- 202 OUTREACH ACTIVITIES BY RADIOTHERAPY CENTRES IN ONTARIO** Pierre-Yves McLaughlin¹, Michael Brundage¹, Padraig Warde², Eric Guttierrez³, William J Mackillop¹; ¹Queen's University, Kingston, ON; ²University of Toronto, Toronto, ON; ³Cancer Care Ontario, Toronto, ON
- 203 ADVANCED CANCER PATIENTS' PERSPECTIVES ON A VIDEO DECISION SUPPORT AID USED TO ENHANCE GOALS OF CARE DISCUSSIONS** Petra Grendarova, Marilynne Hebert; University of Calgary, Calgary, AB
- 204 RADIOTHERAPY FOR THE PROPHYLAXIS OF HETEROTOPIC OSSIFICATION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS** Srinivas Raman¹, Milica Milakovic², Marko Popovic², May Tsao¹, Edward Chow¹; ¹University of Toronto, ON; ²McMaster University, Hamilton, ON
- 205 RADIOSURGERY, TELEMEDICINE AND THE CLINICAL SPECIALIST RADIATION THERAPIST: ENHANCING ACCESS TO CARE** Julie Blain¹, Jeffrey Greenspoon², William McMillan², Carol Potvin², Laura Walsh³, Michelle Aspden³, Anand Swaminath²; ¹Juravinski Cancer Centre, Hamilton, ON; ²McMaster University, Hamilton, ON; ³Ontario Telemedicine Network, Hamilton, ON
- 206 POPULATION BENEFIT OF OPTIMALLY UTILIZED RADIOTHERAPY FOR PROSTATE CANCER: BIOCHEMICAL CONTROL AND OVERALL SURVIVAL** Timothy Hanna¹, Geoff Delaney², Stephen Thompson², Michael Barton²; ¹Cancer Centre of Southeastern Ontario, Kingston, ON; ²Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Ingham Institute, Sydney, New South Wales, Australia
- 207 EVALUATIONS OF HEALTH ECONOMICS IN RADIATION ONCOLOGY: A SYSTEMATIC REVIEW** Timothy K Nguyen¹, Chris D Goodman¹, Gabriel Boldt¹, Andrew Warner¹, David A Palma¹, George B Rodrigues¹, Michael Lock¹, Gregory S Zaric², Alexander V Louie¹; ¹London Regional Cancer Program, London, ON; ²Western University, London, ON
- 208 MAKING MOLEHILLS OUT OF A MOUNTAIN: ONE CENTRE'S EXPERIENCE WITH A NEW SCHEDULING STRATEGY TO DIMINISH WORKLOAD VARIATIONS IN RESPONSE TO INCREASED TREATMENT DEMANDS** Alexandra Waters¹, Cédric Filion², Marie-Pier Chagnon², Moein Alizadeh³, Jason Pun⁴, Fred Ashbury⁴; ¹Université de Montréal, Montreal, QC; ²Centre Intégré de Cancérologie de Laval, Laval, QC; ³Université de Montréal, Laval, QC; ⁴Intelligent Improvement Consultants I²C, Toronto, ON

- 209 HYPOFRACTIONATION VERSUS CONVENTIONALLY FRACTIONATED RADIOTHERAPY FOR LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: CLINICAL AND ECONOMIC EVALUATION IN REAL-LIFE SETTING** Fabio Cury, Jason Hu, Sergio Faria, Armen Aprikian, Luis Souhami, George Shenouda, Marie Duclos, Marc David, Alice Dragomir; McGill University Health Centre, Montreal, QC
- 211 AQUA – A NEW GENERATION, FULLY CPQR-COMPLIANT RECORD AND VERIFYING SYSTEM FOR ROUTINE RADIATION THERAPY QUALITY ASSURANCE** Iulian Badragan¹, Brandon Vangenderen¹, Amanda Harder², Tamara Doubroff², Genoveva Badragan¹; ¹University of Fraser Valley, Abbotsford, BC; ²Abbotsford, BC
- 212 TOWARDS DUAL RESPIRATORY AND CARDIAC GATED RADIOTHERAPY** Anand Karvat¹, Kirpal Kohli¹, Ash Parameswaran², Jeff Liu², Steven Thomas³, Devin Schellenberg¹; ¹British Columbia Cancer Agency, Fraser Valley, Surrey, BC; ²Simon Fraser University, Burnaby, BC; ³British Columbia Cancer Agency, Vancouver, Vancouver, BC
- 213 LONG TERM QUALITY OF LIFE FOR PATIENTS WITH CERVICAL CANCER RECEIVING CURATIVE TREATMENT** Katelyn Bignell¹, Heather Unsworth², Jennifer Croke³; ¹Laurentian University, St John's, NL; ²Michener Institute, Toronto, ON; ³Memorial University, St John's, NL
- 214 A COMPARISON OF RIGID TO DEFORMABLE REGISTRATION FOR DOSE ESCALATION TO THE DOMINANT LESION IN HDR PROSTATE BRACHYTHERAPY (HDRBT)** Juanita Crook, Deidre Batchelar, Annie Collins, Jasbir Jaswal, Matt Schmid, Francois Bachand; University of British Columbia, Kelowna, BC
- 215 PREPARATION AND PLANNING OF A MULTI-ARC VMAT RADIATION THERAPY TECHNIQUE FOR FULL SCALP TREATMENT** Amber Bardock¹, Stephanie Berkelaar¹, Dawn Gillund¹, Kristine McGee¹, Islam Mohamed², Claude Lapointe¹, Cynthia Araujo²; ¹Kelowna, BC; ²University of British Columbia, Kelowna, BC
- 216 SINGLE-ISOCENTER VOLUMETRIC MODULATED ARC THERAPY OR INTENSITY-MODULATED RADIOSURGERY FOR TWO OR MORE LUNG LESIONS** Kimmen Quan, Karen Xu, Zachary Horne, David Clump, Ron Lalonde, Steven Burton, Dwight Heron; University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
- 217 RBAPP: USAGE PATTERNS AND EVALUATION OF A MOBILE APPLICATION FOR RADIOBIOLOGY CALCULATIONS IN RADIATION ONCOLOGY** Derek Tsang¹, Christopher Townsend², Xingshan Cao², Ewa Szumacher¹; ¹University of Toronto, Toronto, ON; ²Sunnybrook Health Sciences Centre, Toronto, ON
- 218 DOSIMETRIC AND TREATMENT DELIVERY PARAMETRIC EVALUATION OF VOLUMETRIC MODULATED ARC THERAPY IN RETROPERITONEAL SARCOMA PATIENTS** Amandeep Taggar, James Grafe, Darren Graham, Elizabeth Kurien; University of Calgary, Calgary, AB
- 219 SINGLE INSTITUTE EXPERIENCE OF USING ON LINE RADIOTHERAPY PLAN EVALUATOR TOOL FOR STEREOTAXIC RADIOSURGERY** Shakir Shakir, Khalil Sultanem, Thierry Muanza, Gabriela Stroian, Francois DeBlois, Michael Fan; McGill University, Montreal, QC
- 220 A CASE OF SYNCHRONOUS BREAST AND BILATERAL LUNG CANCERS: LITERATURE REVIEW AND CONSIDERATIONS FOR RADIATION TREATMENT PLANNING** Chunzi Jenny Jin, Conrad B Falkson; Queen's University, Kingston, ON
- 221 DOSIMETRIC IMPACT OF THE ACUROS ADVANCED DOSE CALCULATION ALGORITHM ON INTERNAL MAMMARY CHAIN NODAL COVERAGE IN BREAST CANCER PATIENTS RECEIVING ADJUVANT REGIONAL NODAL IRRADIATION** Majed Alghamdi, Ivo Olivotto, Rao Khan, Tien Phan; University of Calgary, Calgary, AB
- 223 CLINICAL SURVEILLANCE VERSUS CLINICAL AND MRI SURVEILLANCE FOR NEW BRAIN METASTASES AFTER RADIOSURGERY ALONE AS INITIAL TREATMENT FOR 1-3 BRAIN METASTASES: A FEASIBILITY SURVEY** Jeffrey Greenspoon¹, Kristy Yiu²; ¹Juravinski Cancer Centre, Hamilton, ON; ²McMaster University, Hamilton, ON
- 224 COST-EFFECTIVENESS ANALYSIS OF PREOPERATIVE VERSUS POSTOPERATIVE RADIOTHERAPY IN RESECTABLE EXTREMITY SOFT TISSUE SARCOMA** Melody Xuan Lu Qu¹, Nabil Wasif², Alexander Louie³; ¹Queen's University, Kingston, ON; ²Mayo Clinic, Phoenix, AZ, USA; ³London Regional Cancer Program, London, ON
- 225 POST-OPERATIVE HYPERFRACTIONATED ACCELERATED RE-IRRADIATION IN PATIENTS WITH RADIATION-ASSOCIATED SECONDARY ANGIOSARCOMA OF THE BREAST** Elysia Donovan, Thomas Corbett, Barbara Heller; McMaster University, Hamilton, ON
- 226 TREATMENT-INDUCED HEARING LOSS AND COCHLEAR DOSES: DOES RADIATION STILL PLAY A ROLE IN THE IMRT ERA?** Jelena Lukovic¹, Wendy Teft², Linda Lee², Anthony Nichols¹, Christina Parker², Maureen Trinear¹, Eric Winquist¹, John Yoo³, David Palma¹, Richard Kim²; ¹London Regional Cancer Program, London, ON; ²Western University, London, ON; ³London Health Sciences Centre, London, ON
- 227 THE IMPACT OF PROSTATE CANCER ON THE SEX LIVES OF MEN-WHO-HAVE-SEX-WITH-MEN (MSM): A QUALITATIVE STUDY** Tsz Kin Lee¹, Ariel Handy², Richard Wassersug², Lori Brotto², Winkle Kwan³, John Oliffe², Gary Dowsett⁴; ¹British Columbia Cancer Agency, Kelowna, BC; ²University of British Columbia, Vancouver, BC; ³British Columbia Cancer Agency, Surrey, BC; ⁴La Trobe University, Melbourne, BC
- 228 IMPLEMENTING A WELL FOLLOW-UP CARE PLAN FOR COLORECTAL CANCER PATIENTS: QUALITY ASSURANCE AND LESSONS LEARNED** Chunzi Jenny Jin, Jim Biagi, Hugh Langley, Candice Christmas, Julia Niblett, Aamer Mahmud; Queen's University, Kingston, ON

imagine




...advanced technology with
the patient in mind



Neuroscience



Oncology



Treatment Planning &
Information Software



Brachytherapy

With Elekta, it's reality.

Every day, more than 100,000 patients worldwide are diagnosed, treated or receive follow-up with the help of a solution from Elekta. Through innovation and collaboration, we are advancing patient care.

4513 371 1128 02:13

More at elekta.com





BETTER. TOGETHER.

OUR COLLECTIVE ENERGY WILL HELP IMPROVE
THE WAY WE FIGHT CANCER.

Radiation technology and software are just part of the cancer-fighting equation—and they can only reach their full potential when in the hands of the people who put them to use every day. That's why we're dedicated to working alongside you as the world of oncology continues to change. Because sophisticated treatment options, better insights and cohesive care are best achieved as a team.

Visit us at CARO 2015. Booth #19-20.

Learn more at varian.com

VARIAN
medical systems
A partner for **life**

*Brachytherapy
& Biology*

CARO2015

SEPTEMBER 9-12 | KELOWNA, BC

29th ANNUAL SCIENTIFIC MEETING

SPONSORS

PLATINUM

Elekta Inc.

Varian

BRONZE

Abbvie Corp

AstraZeneca

Hoffmann-La Roche Ltd

SANOFI Canada

SUPPORTER

Bayer Inc.

EXHIBITORS

3M Canada

Accuray

AMGEN

Best Medical Canada

BioSynt Pharma Inc.

CAMRT

Carl Zeiss Canada Ltd.

CDR Systems

CPQR

Donaldson Marphil Medical Inc.

Genomic Health


Genzyme

Janssen Inc.

MIM Software Inc.

Philips Healthcare

Takeda Canada Inc.



caro acro

BANFF, AB • September 14-17

30 YEARS

QUALITY CARE CURE

2016

ANNUAL
SCIENTIFIC
MEETING

Fairmont Banff Springs